var title_f20_40_21120="Toxoplasma chorioretinitis";
var content_f20_40_21120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Toxoplasma chorioretinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chorioretinitis characteristic of toxoplasmosis. A pigmented scar is seen with an adjacent area of active chorioretinitis. The diagnosis of toxoplasmosis is based primarily on the appearance of the chorioretinal lesion rather than serologic studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21120=[""].join("\n");
var outline_f20_40_21120=null;
var title_f20_40_21121="Types of PD catheters";
var content_f20_40_21121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of peritoneal dialysis catheters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representations of the Tenckhoff, Toronto Western Hospital, and Swan Neck Missouri peritoneal dialysis catheters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Khanna, R, Nolph, KD, Oreopoulos, DG (Eds). The Essentials of Peritoneal Dialysis, Kluwer Academic Publishers, p. 20.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21121=[""].join("\n");
var outline_f20_40_21121=null;
var title_f20_40_21122="Monobenzone: Drug information";
var content_f20_40_21122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Monobenzone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/5/38995?source=see_link\">",
"    see \"Monobenzone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vitiligo:",
"     </b>",
"     Topical: Apply 2-3 times daily; once depigmentation is obtained, may apply as needed (usually 2 times/week)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F197272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vitiligo:",
"     </b>",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical: 20% (35 g) [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F197255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply thin layer to affected area.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Final depigmentation in extensive vitiligo",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning sensation, depigmentation of skin distant to application site, dermatitis, irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to monobenzone or any component of the formulation; use as cosmetic skin bleach; use as hydroquinone substitute",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Skin will be sensitive to the sun following application and for the rest of the patient's life; sunscreen must be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Rarely indicated in children as depigmentation is permanent. Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only. For use only as a final depigmentation in extensive vitiligo; not recommended for use in freckling, hyperpigmentation caused by photosensitization, melasma, hyperpigmentation resulting from skin inflammation, cafe-au-lait spots, pigmented nevi, or malignant melanoma.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benoquin (IN);",
"     </li>",
"     <li>",
"      Monobenzone (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases excretion of melanin from melanocytes; causes melanocyte destruction and permanent depigmentation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 1-4 months",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10158 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21122=[""].join("\n");
var outline_f20_40_21122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197277\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197267\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197272\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197268\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197253\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197242\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197255\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197275\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197258\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197246\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299725\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221766\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197251\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197260\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197269\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197261\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197245\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197257\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10158\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10158|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/5/38995?source=related_link\">",
"      Monobenzone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21123="Amniotic band sequence involving GI tract and a limb";
var content_f20_40_21123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Two images from fetal a survey at 20 weeks of gestation in a fetus with amniotic band sequence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first image, which was obtained during a fetal survey,&nbsp;(A) shows an anterior abdominal wall defect adjacent to the cord insertion site, with free floating loops of bowel in the amniotic fluid. This is the appearance of a gastroschisis. The second image (B) shows the leg with a constriction band. There were many other regions of amputations and constriction bands in this fetus, leading to the diagnosis of amniotic band sequence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21123=[""].join("\n");
var outline_f20_40_21123=null;
var title_f20_40_21124="Plain x-ray normal ankle";
var content_f20_40_21124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Plain x-ray normal ankle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    X-ray of the normal right ankle in the anteroposterior (A), oblique&nbsp;(B), and lateral (C) projections. Image B exposes the mortise-like configuration of the joint, and this projection is commonly referred to as a mortise view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21124=[""].join("\n");
var outline_f20_40_21124=null;
var title_f20_40_21125="Solitary rectal ulcer syndrome";
var content_f20_40_21125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Solitary rectal ulcer syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21125/contributors\">",
"     David J Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21125/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/40/21125/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary rectal ulcer syndrome is an uncommon rectal disorder that can present with bleeding, passage of mucus, straining during defecation, and a sense of incomplete evacuation. The lesion was first reported in 1829 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/1\">",
"     1",
"    </a>",
"    ], but its clinical manifestations and histopathology were not described until 1969 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/2\">",
"     2",
"    </a>",
"    ]. Because it is rare, its incidence is uncertain, but has been estimated in one study to be 1 in 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/3\">",
"     3",
"    </a>",
"    ]. In one retrospective study of 80 patients, the median age was 48 years with a range of 14 to 76 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/4\">",
"     4",
"    </a>",
"    ]. Men and women appear to be affected equally although gender differences have been suggested in various reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The name of the syndrome is misleading, since patients can often present with lesions that are neither solitary nor ulcerated. The lesions are located in the anterior rectal wall within 10 cm of the anal verge in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic and radiologic findings vary and can include mucosal ulcerations, polypoid and mass lesions (mimicking rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/5\">",
"     5",
"    </a>",
"    ]), or simply erythema. As a result, misdiagnosis is common. In one study, as many as 26 percent of patients had been initially diagnosed incorrectly, most commonly as having a nonspecific ulcer, inflammatory bowel disease, or adenomatous changes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms are variable or may be absent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In an illustrative series the most common symptoms were rectal bleeding (56 percent), straining (28 percent), and pelvic fullness (23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/6\">",
"     6",
"    </a>",
"    ]. Mucous discharge, incontinence, tenesmus, and pain were less frequently described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the solitary rectal ulcer is incompletely understood. However, a number of factors appeared to have a causative role in individual reports. It is possible that different etiologies may contribute to the development of the final lesion.",
"   </p>",
"   <p>",
"    A common observation in a number of reports is rectal prolapse and paradoxical contraction of the puborectalis muscle, which can result in rectal trauma by two different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolapsed rectal mucosa is forced downward due to the pressures generated by the rectum during defecation. The opposing force of the paradoxical contraction of the puborectalis muscle can generate high pressures within the rectum and lead to mucosal ischemia, thus predisposing to ulceration.",
"     </li>",
"     <li>",
"      Shear forces on the rectal mucosa caused by the contraction of the puborectalis muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, excessive puborectalis contraction is not found in all patients with solitary rectal ulcer. Furthermore, it is unclear whether prolapse causes ulceration, or whether they are both varying manifestations of a similar disease process. It is also possible that prolapse is an associated condition rather than a causative one, a hypothesis supported by a study in which surgical correction of the rectal prolapse had no significant impact on symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case control study compared anorectal physiology and defecation proctography in 25 patients with solitary rectal ulcer syndrome with matched controls with either outlet obstruction (25 patients), overt rectal prolapse without any mucosal change (25 patients), or overt rectal prolapse with mucosal changes (14 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with solitary rectal ulcer syndrome more frequently had increasing anal pressure at strain, paradoxical puborectalis contraction and prolapse of the inner circular smooth muscle of the rectum, and less frequently had complete rectal emptying compared with the control groups. Compared with patients with overt rectal prolapse, mean resting and squeezing anal pressures were significantly higher.",
"   </p>",
"   <p>",
"    Direct digital trauma has also been implicated, since many patients have a history of constipation and report attempts at manual disimpaction. However, a number of lesions have been described that were beyond the reach of an inserted finger.",
"   </p>",
"   <p>",
"    A possible hormonal cause has also been proposed. A case report documented a woman with solitary rectal ulcer syndrome that resolved during two pregnancies but recurred when she was not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histology of solitary rectal ulcer has a characteristic appearance that includes a thickened mucosal layer with distortion of the crypt architecture. The lamina propria is replaced with smooth muscle and collagen leading to hypertrophy and disorganization of the muscularis mucosa, an appearance that has been referred to as \"fibromuscular obliteration\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar changes have been described in patients with colitis cystica profunda disease, another rare disorder characterized by the presence of submucosal, mucus-filled cysts most often affecting the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/13\">",
"     13",
"    </a>",
"    ]. The presence of collagen infiltration of the lamina propria can be helpful for distinguishing solitary rectal ulcer syndrome from Crohn's disease, ulcerative colitis, and chronic ischemic colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of solitary rectal ulcer syndrome is usually based upon clinical symptoms combined with the endoscopic and histologic findings described above. The differential diagnosis includes Crohn's disease, ulcerative colitis, chronic ischemic colitis, malignancy, amebiasis, lymphogranuloma venereum, secondary syphilis, endometriosis, and colitis cystica profunda [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transrectal and endoanal ultrasound can show thickening of the rectal wall and internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Another finding is the loss of distinction between the planes of the mucosa and muscularis propria.",
"   </p>",
"   <p>",
"    Defecation proctography can demonstrate rectal prolapse as well as incomplete or delayed rectal emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/17\">",
"     17",
"    </a>",
"    ]. In a study of 53 patients, 40 (75 percent) had abnormalities on proctography, most commonly internal and external rectal prolapse and delayed rectal emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/17\">",
"     17",
"    </a>",
"    ]. Other tests of anorectal function have not been consistently useful in diagnosis or in predicting a response to therapy. The American Gastroenterological Association (AGA) guideline for anorectal testing techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/18\">",
"     18",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . Findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may include a rectal stricture, granularity of the mucosa, and thickened rectal folds, all of which are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of solitary rectal ulcer syndrome depends upon symptoms and whether rectal prolapse is present. Observation alone or treatment with bulk laxatives, bowel retraining, and reassurance are reasonable in patients who are asymptomatic or minimally symptomatic. On the other hand, surgery (typically abdominal rectopexy) may be required in symptomatic patients with rectal prolapse since conservative therapy is unlikely to be successful. A variety of other surgical procedures have been described in patients without rectal prolapse including local excision, colonic resection, and rarely a diverting colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]. Treatment outcome is variable; one report found that a subset of patients has continued anorectal dysfunction and decreased quality of life regardless of the treatment approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative management is appropriate for patients who experience only mild symptoms but do not have rectal prolapse. This may include stool bulking agents and retraining of bowel habits using biofeedback. The goals of therapy are to manage constipation and to prevent paradoxical puborectalis contraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .) In one report, these measures were successful in 19 percent of 59 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, no patients with rectal prolapse derived any benefit from this treatment plan. Other reports have also suggested improvement with biofeedback [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. However, the durability of benefit is unclear and thus repeat treatment may be needed. A study that included 13 patients found that approximately one-half of the seven who initially responded to biofeedback relapsed within 36 months after training [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/23\">",
"     23",
"    </a>",
"    ]. Successful treatment with topical glucocorticoids, salicylates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    enemas, and botulinum toxin has been described but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/7,24-29\">",
"     7,24-29",
"    </a>",
"    ]. One report described control of bleeding after multiple sessions of argon plasma coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is appropriate for patients with full-thickness or mucosal rectal prolapse, or with symptoms unresponsive to conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/31\">",
"     31",
"    </a>",
"    ]. Surgical options include local excision, diversion, or rectopexy. Local excision or suturing of the lesions has been performed with some success, but with uncertain long-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/32\">",
"     32",
"    </a>",
"    ]. Rectopexy has also been performed with the intent of correcting rectal prolapse. In one small study, this procedure resulted in symptomatic improvement in 83 percent of patients with the polypoid form of solitary rectal ulcer, and in 67 percent of patients with an ulcerated lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/6\">",
"     6",
"    </a>",
"    ]. Fecal diversion approaches have also improved patient symptoms and can be considered in patients who have failed other surgical modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcome of surgery was described in a report that included 76 patients who were followed for a median of 7.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/34\">",
"     34",
"    </a>",
"    ]. The most common surgical procedure was a rectopexy, which had failed in 22 of 49 patients (44 percent) by the end of follow-up. Further surgery was required in 19 of these patients, including rectal resection with coloanal anastomosis and colostomy. Overall, anti-prolapse operations resulted in a satisfactory long-term outcome in approximately 60 percent of patients.",
"   </p>",
"   <p>",
"    Another series included 11 patients who underwent laparoscopic mesh rectopexy and were followed for a median of approximately seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21125/abstract/35\">",
"     35",
"    </a>",
"    ]. Complete endoscopic healing of the ulcer was demonstrated in 11 patients up to one year postoperatively but the ulcer recurred subsequently in one patient. Of seven patients with long-term follow-up, none experienced endoscopic recurrence, although one patient had persistent symptoms. The authors concluded that laparoscopic mesh rectopexy may offer a minimally invasive option for selected patients who remain symptomatic despite maximal conservative therapy, but further studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solitary rectal ulcer syndrome is an uncommon rectal disorder that can present with bleeding, passage of mucus, straining during defecation, and a sense of incomplete evacuation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The name of the syndrome is misleading, since patients can often present with lesions that are neither solitary nor ulcerated. The lesions are located in the anterior rectal wall within 10 cm of the anal verge in the majority of patients. Endoscopic findings vary and can include mucosal ulcerations, polypoid lesions, or simply erythema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually based upon clinical symptoms combined with the endoscopic and histologic findings described above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment depends upon symptoms and whether rectal prolapse is present. We suggest observation alone or treatment with bulk laxatives, bowel retraining, and reassurance in patients who are asymptomatic or minimally symptomatic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Conservative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgery (typically abdominal rectopexy) in symptomatic patients with rectal prolapse since conservative therapy is unlikely to be successful (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cruveilhier J. Ulcere chronique du rectum. In: Anatomie pathologique du corps humain, JB Bailliere, Paris 1829.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/2\">",
"      Madigan MR, Morson BC. Solitary ulcer of the rectum. Gut 1969; 10:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/3\">",
"      Martin CJ, Parks TG, Biggart JD. Solitary rectal ulcer syndrome in Northern Ireland. 1971-1980. Br J Surg 1981; 68:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/4\">",
"      Tjandra JJ, Fazio VW, Church JM, et al. Clinical conundrum of solitary rectal ulcer. Dis Colon Rectum 1992; 35:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/5\">",
"      Blanco F, Frasson M, Flor-Lorente B, et al. Solitary rectal ulcer: ultrasonographic and magnetic resonance imaging patterns mimicking rectal cancer. Eur J Gastroenterol Hepatol 2011; 23:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/6\">",
"      Tjandra JJ, Fazio VW, Petras RE, et al. Clinical and pathologic factors associated with delayed diagnosis in solitary rectal ulcer syndrome. Dis Colon Rectum 1993; 36:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/7\">",
"      Bulut T, Canbay E, Yamaner S, et al. Solitary rectal ulcer syndrome: exploring possible management options. Int Surg 2011; 96:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/8\">",
"      Ong J, Lim KH, Lim JF, Eu KW. Solitary caecal ulcer syndrome: our experience with this benign condition. Colorectal Dis 2011; 13:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/9\">",
"      Morio O, Meurette G, Desfourneaux V, et al. Anorectal physiology in solitary ulcer syndrome: a case-matched series. Dis Colon Rectum 2005; 48:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/10\">",
"      Rao SS, Ozturk R, De Ocampo S, Stessman M. Pathophysiology and role of biofeedback therapy in solitary rectal ulcer syndrome. Am J Gastroenterol 2006; 101:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/11\">",
"      Halligan S, Nicholls RJ, Bartram CI. Evacuation proctography in patients with solitary rectal ulcer syndrome: anatomic abnormalities and frequency of impaired emptying and prolapse. AJR Am J Roentgenol 1995; 164:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/12\">",
"      Sood SK, Garner JP, Amin SN. Spontaneous resolution of solitary rectal ulcer syndrome during pregnancy: report of a case. Dis Colon Rectum 2008; 51:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/13\">",
"      Levine DS. \"Solitary\" rectal ulcer syndrome. Are \"solitary\" rectal ulcer syndrome and \"localized\" colitis cystica profunda analogous syndromes caused by rectal prolapse? Gastroenterology 1987; 92:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/14\">",
"      Daya D, O'Connell G, DeNardi F. Rectal endometriosis mimicking solitary rectal ulcer syndrome. Mod Pathol 1995; 8:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/15\">",
"      Halligan S, Sultan A, Rottenberg G, Bartram CI. Endosonography of the anal sphincters in solitary rectal ulcer syndrome. Int J Colorectal Dis 1995; 10:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/16\">",
"      Marshall M, Halligan S, Fotheringham T, et al. Predictive value of internal anal sphincter thickness for diagnosis of rectal intussusception in patients with solitary rectal ulcer syndrome. Br J Surg 2002; 89:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/17\">",
"      Goei R, Baeten C, Janevski B, van Engelshoven J. The solitary rectal ulcer syndrome: diagnosis with defecography. AJR Am J Roentgenol 1987; 149:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/18\">",
"      Barnett JL, Hasler WL, Camilleri M. American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Gastroenterology 1999; 116:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/19\">",
"      Britto E, Borges AM, Swaroop VS, et al. Solitary rectal ulcer syndrome. Twenty cases seen at an oncology center. Dis Colon Rectum 1987; 30:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/20\">",
"      Millward SF, Bayjoo P, Dixon MF, et al. The barium enema appearances in solitary rectal ulcer syndrome. Clin Radiol 1985; 36:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/21\">",
"      Halligan S, Nicholls RJ, Bartram CI. Proctographic changes after rectopexy for solitary rectal ulcer syndrome and preoperative predictive factors for a successful outcome. Br J Surg 1995; 82:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/22\">",
"      Meurette G, Siproudhis L, Regenet N, et al. Poor symptomatic relief and quality of life in patients treated for \"solitary rectal ulcer syndrome without external rectal prolapse\". Int J Colorectal Dis 2008; 23:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/23\">",
"      Malouf AJ, Vaizey CJ, Kamm MA. Results of behavioral treatment (biofeedback) for solitary rectal ulcer syndrome. Dis Colon Rectum 2001; 44:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/24\">",
"      Zargar SA, Khuroo MS, Mahajan R. Sucralfate retention enemas in solitary rectal ulcer. Dis Colon Rectum 1991; 34:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/25\">",
"      Kochhar R, Mehta SK, Aggarwal R, et al. Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum 1990; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/26\">",
"      H&ouml;pfner M, Nitsche R, Rohr A, et al. Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis. Scand J Gastroenterol 2001; 36:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/27\">",
"      Jarrett ME, Emmanuel AV, Vaizey CJ, Kamm MA. Behavioural therapy (biofeedback) for solitary rectal ulcer syndrome improves symptoms and mucosal blood flow. Gut 2004; 53:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/28\">",
"      Vaizey CJ, Roy AJ, Kamm MA. Prospective evaluation of the treatment of solitary rectal ulcer syndrome with biofeedback. Gut 1997; 41:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/29\">",
"      Dehghani SM, Haghighat M, Imanieh MH, Geramizadeh B. Solitary rectal ulcer syndrome in children: a prospective study of cases from southern Iran. Eur J Gastroenterol Hepatol 2008; 20:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/30\">",
"      Somani SK, Ghosh A, Avasthi G, et al. Healing of a bleeding solitary rectal ulcer with multiple sessions of argon plasma. Gastrointest Endosc 2010; 71:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/31\">",
"      Torres C, Khaikin M, Bracho J, et al. Solitary rectal ulcer syndrome: clinical findings, surgical treatment, and outcomes. Int J Colorectal Dis 2007; 22:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/32\">",
"      Niv Y, Bat L. Solitary rectal ulcer syndrome--clinical, endoscopic, and histological spectrum. Am J Gastroenterol 1986; 81:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/33\">",
"      Stavorovsky M, Weintroub S, Ratan J, Rozen P. Successful treatment of a benign solitary rectal ulcer by temporary diverting sigmoidostomy: report of a case. Dis Colon Rectum 1977; 20:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/34\">",
"      Sitzler PJ, Kamm MA, Nicholls RJ, McKee RF. Long-term clinical outcome of surgery for solitary rectal ulcer syndrome. Br J Surg 1998; 85:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21125/abstract/35\">",
"      Tweedie DJ, Varma JS. Long-term outcome of laparoscopic mesh rectopexy for solitary rectal ulcer syndrome. Colorectal Dis 2005; 7:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2572 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21125=[""].join("\n");
var outline_f20_40_21125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21126="Seborrheic keratosis 4";
var content_f20_40_21126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seborrheic keratoses are common, benign, yellowish to brown, raised lesions that feel slightly greasy and velvety or warty. Typically multiple and symmetrically distributed on the trunks of older people, they may also appear on the face and elsewhere.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sauer, GC. Manual of Skin Diseases, 5th Edition, JB Lippincott, Philadelphia 1985. Copyright &copy; 1985 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21126=[""].join("\n");
var outline_f20_40_21126=null;
var title_f20_40_21127="Vardenafil: Drug information";
var content_f20_40_21127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vardenafil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/36/13893?source=see_link\">",
"    see \"Vardenafil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levitra&reg;;",
"     </li>",
"     <li>",
"      Staxyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levitra&reg;;",
"     </li>",
"     <li>",
"      Staxyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-5 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral disintegrating tablets should not be used interchangeably with film-coated tablets; patients requiring a dose other than 10 mg should use the film-coated tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erectile dysfunction:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Film-coated tablet (Levitra&reg;): 10 mg 60 minutes prior to sexual activity; dosing range: 5-20 mg; to be given as one single dose and not given more than once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral disintegrating tablet (Staxyn&trade;): 10 mg 60 minutes prior to sexual activity; maximum: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alpha-blocker",
"     </i>",
"     (dose should be stable at time of vardenafil initiation):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Film-coated tablet (Levitra&reg;): Initial vardenafil dose: 5 mg/24 hours; if an alpha-blocker is added to vardenafil therapy, it should be initiated at the smallest possible dose and titrated carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral disintegrating tablet (Staxyn&trade;): Do not use to initiate therapy. Initial therapy should be with film-coated tablets at lower doses. Patients who have previously used film-coated tablets may be switched to oral disintegrating tablets as recommended by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Film-coated tablet (Levitra&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Atazanavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Clarithromycin:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Darunavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Erythromycin:",
"     </i>",
"     Maximum vardenafil dose: 5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Fosamprenavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Fosamprenavir/ritonavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Indinavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Itraconazole:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     200 mg/day: Maximum vardenafil dose: 5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     400 mg/day: Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Ketoconazole:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     200 mg/day: Maximum vardenafil dose: 5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     400 mg/day: Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Lopinavir/ritonavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Nelfinavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Ritonavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Saquinavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Tipranavir:",
"     </i>",
"     Maximum vardenafil dose: 2.5 mg/72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral disintegrating tablet (Staxyn&trade;): Concurrent use not recommended with potent or moderate CYP3A4 inhibitors (atazanavir, clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erectile dysfunction: Elderly &ge;65 years: Oral: Initial: 5 mg 60 minutes prior to sexual activity; to be given as one single dose and not given more than once daily.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment not needed for mild, moderate, or severe impairment; use not recommended in patients on hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Child-Pugh class A: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Child-Pugh class B:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Film-coated tablet (Levitra&reg;): Initial: 5 mg 60 minutes prior to sexual activity (maximum dose: 10 mg); to be given as one single dose and not given more than once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral disintegrating tablet (Staxyn&trade;): Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Child-Pugh class C: Has not been studied; use is not recommended by the manufacturer",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levitra&reg;: 2.5 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Staxyn&trade;: 10 mg [contains phenylalanine 1.01 mg/tablet; peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food, 60 minutes prior to sexual activity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral disintegrating tablet should not be removed from blister pack until administered. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds; do not take with liquid. Do not crush, split, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of erectile dysfunction (ED)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vardenafil may be confused with sildenafil, tadalafil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levitra&reg; may be confused with Kaletra&reg;, Lexiva&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (14% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3% to 4%), nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%), CPK increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (9%), nasal congestion (3%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abnormal ejaculation, amnesia (transient global), anaphylactic reaction, angina, angioedema, arthralgia, dyspnea, hearing decreased, hearing loss, hyper-/hypotension, insomnia, liver function tests abnormal, MI, myalgia, nonarteritic ischemic optic neuropathy (NAION), orthostatic hypotension, pain, photophobia, photosensitivity, priapism, pruritus, rash, somnolence, syncope, tachycardia, tinnitus, ventricular tachyarrhythmia, vertigo, vision abnormal, visual acuity reduced, visual field defects, vision loss (temporary or permanent)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vardenafil or any component of the formulation; concurrent (regular or intermittent) use of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy); may be more sensitive to hypotensive actions. Concurrent use with alpha-adrenergic antagonist therapy may cause symptomatic hypotension; patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Avoid or limit concurrent substantial ethanol  consumption as this may increase the risk of symptomatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Has been reported (rarely) with use. Instruct  patients to seek immediate medical attention if erection persists &gt;4 hours. Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss: Vision loss may occur rarely and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Risk may be increased with history of vision loss. Other risk factors for NAION include low cup-to-disc ratio (&ldquo;crowded disc&rdquo;), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Safety and efficacy were not studied in patients with known degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is not recommended in patients with hypotension (&lt;90/50 mm Hg); uncontrolled hypertension (&gt;170/100 mm Hg); unstable angina or angina during intercourse; life-threatening arrhythmias, stroke, or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina. Safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Congenital QT prolongation: Not recommended for use in patients with congenital QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment is needed. Safety and efficacy have not been studied in patients with severe hepatic impairment (Child-Pugh class C); therefore, use in these patients is not recommended. Per the manufacturer, the oral disintegrating tablet should not be used in patients with moderate-to-severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been studied in patients with end-stage renal disease requiring dialysis, therefore, use in these patients is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alpha-blockers: Use with caution in patients taking alpha-blockers; may cause hypotension. Safety of this combination may be affected by other antihypertensives and intravascular volume depletion. Patients should be hemodynamically stable prior to initiating therapy. Initiate vardenafil at the lowest recommended dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Use with caution in patients taking medications known to prolong the QT interval. Avoid use in patients taking Class Ia or III antiarrhythmics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use film-coated tablet with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); dosage reductions may be necessary; consider alternative agents that avoid or lessen the potential for CYP-mediated interactions. Avoid use of the oral disintegrating tablet with moderate-to-strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nitrates: Concomitant use with all forms of nitrates is contraindicated. If nitrate administration is medically necessary, it is not known when nitrates can be safely administered following the use of vardenafil; the ACC/AHA 2007 guidelines support administration of nitrates only if 24 hours have elapsed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other treatments for erectile dysfunction: Safety and efficacy with other treatments for erectile dysfunction have not been established; concurrent use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dosage reduction may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Some products may contain sorbitol; do not use in patients with fructose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Potential underlying causes of erectile dysfunction should be evaluated prior to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers.  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Phosphodiesterase 5 Inhibitors may enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Vardenafil. Management: Limit vardenafil maximum dose to 2.5 mg every 24 hours and monitor closely for symptoms of vardenafil toxicity (including hypotension, visual changes, syncope, and priapism) during treatment with boceprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Vardenafil. Management: Recommendations regarding the concomitant use of vardenafil with clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). Consult appropriate product labelings.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Vardenafil. Management: Recommendations regarding use of vardenafil with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate product vary based on specific vardenafil brand and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vardenafil. Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Vardenafil. Management: Limit dose of vardenafil film-coated tablets (Levitra)  to 5 mg per 24 hours with concomitant use of erythromycin. Concomitant use of vardenafil orally disintegrating tablets (Staxyn) with erythromycin is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil doses to a maximum of 5 mg per 24-hour period in patients receiving concurrent therapy with a moderate CYP3A4 inhibitor such as fluconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving itraconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving itraconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Vardenafil. Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving ketoconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving ketoconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Vardenafil. Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Vardenafil. Management: In patients receiving telaprevir, vardenafil dosing should be limited to 2.5 mg per 72-hour period with close monitoring for signs/symptoms of vardenafil toxicity (including hypotension, visual changes, syncope, and priapism).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Ethanol: Substantial consumption of ethanol may increase the risk of hypotension and orthostasis. Lower ethanol consumption has not been associated with significant changes in blood pressure or increase in orthostatic symptoms. Management: Avoid or limit ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meals decrease maximum serum concentration 18% to 50%. Serum concentrations/toxicity may be increased with grapefruit juice. Management: Do not take with a high-fat meal. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, vardenafil is not indicated for use in women. No effects on sperm motility or morphology were observed in healthy males.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F233452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take with or without food. Avoid grapefruit juice. Some products may contain phenylalanine. Some products may contain sorbitol; do not use in patients with fructose intolerance.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F233450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Staxyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (4): $73.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levitra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $841.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $841.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $841.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $841.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for response, adverse reactions, blood pressure, and heart rate.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Levitra (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, RU, SE, SG, SK, SR, SV, TH, TR, TT, TW, VE);",
"     </li>",
"     <li>",
"      Levitra ODT (KP);",
"     </li>",
"     <li>",
"      Vivanza (BG, ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Vardenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by vardenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 208 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95% (parent drug and metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (major), CYP2C and 3A5 (minor); forms metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Film-coated tablet: Elderly (&ge;65 years): AUC increased by 52%; Hepatic impairment (moderate, Child-Pugh class B): AUC increased by 160%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral disintegrating tablet: Elderly (&ge;65 years): AUC increased by 21% more compared to film-coated tablet. When administered with water, AUC decreases by 29%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Vardenafil and metabolite: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~91% to 95% as metabolites); urine (~2% to 6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):1-157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/40/21127/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/40/21127/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/40/21127/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson G, Rosen RC, Kloner RA, et al, &ldquo;The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine,&rdquo;",
"      <i>",
"       J Sex Med",
"      </i>",
"      , 2006, 3(1):28-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/40/21127/abstract-text/16409215/pubmed\" id=\"16409215\" target=\"_blank\">",
"        16409215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McVary KT, &ldquo;Clinical Practice. Erectile Dysfunction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(24):2472-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/40/21127/abstract-text/18077811/pubmed\" id=\"18077811\" target=\"_blank\">",
"        18077811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10172 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21127=[""].join("\n");
var outline_f20_40_21127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233465\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855046\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233485\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233468\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233469\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233470\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233471\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233443\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233430\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233446\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233445\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233483\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233449\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233433\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233479\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233437\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233462\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233439\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233451\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233474\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233452\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233450\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233441\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233453\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233432\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233448\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/36/13893?source=related_link\">",
"      Vardenafil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21128="Hepatic ductopenia and vanishing bile duct syndrome";
var content_f20_40_21128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic ductopenia and vanishing bile duct syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Nancy Reau, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Donald M Jensen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21128/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/40/21128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vanishing bile duct syndrome refers to a group of acquired disorders resulting in progressive destruction and disappearance of the intrahepatic bile ducts and ultimately cholestasis. Ductopenia (a pathologic description) refers to the associated reduction in the number of intrahepatic bile ducts, a process that ultimately leads to cholestasis.",
"   </p>",
"   <p>",
"    The diagnosis is made pathologically, although it can be suggested on imaging tests such as endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) when disease is advanced. There are multiple etiologies that can result in this final common pathologic picture including autoimmune disorders, medications, genetic abnormalities, infectious diseases, and neoplastic disorders. The prognosis and treatment depend on the etiology and degree of injury. This topic will review the anatomy, classification, pathophysiology, diagnosis, and treatment of this heterogeneous group of disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biliary tree is the tubular system of ducts that transports bile from the liver to the small intestine. It is divided into intra- and extrahepatic systems. Few disease states involve both systems, thus allowing for a natural taxonomic separation between the intra- and extrahepatic biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extrahepatic system includes the right and left hepatic ducts, cystic duct, and common bile duct.",
"     </li>",
"     <li>",
"      The intrahepatic biliary tree contains ducts proximal to the right and left hepatic ducts [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"       2",
"      </a>",
"      ]. The intrahepatic system is further divided into intrahepatic large bile ducts (segmental and area ducts), which are grossly visible, and the intrahepatic small bile ducts (septal, interlobular, ductules, and canal of Hering).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diameter of the bile ducts steadily decreases from the liver hilum toward the periphery. The bile ducts, as well as branches of the hepatic artery and portal vein, form a triad in the portal tract. Interlobular bile ducts are identified in portal tracts near arterial branches of similar size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Embryology and development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver, gallbladder, and biliary system all arise embryologically from an outgrowth of the foregut. The cranial portion of this bud develops into liver and intrahepatic bile ducts, while a smaller caudal portion becomes the gallbladder, common bile duct, and cystic duct. Common endodermal cells differentiate into hepatocytes and the epithelial lining of the intrahepatic ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/3\">",
"     3",
"    </a>",
"    ]. The biliary epithelial cells then form a bilayered structure (the ductal plate) around branches of the portal vein. Small dilations between the ductal plate layers develop into the bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductopenia (also referred to as bile duct paucity and vanishing bile duct syndrome) is a descriptive term for interlobular and septal bile duct loss from any cause. It is a well recognized disorder in children but was not described in adults until 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5\">",
"     5",
"    </a>",
"    ]. In both children and adults it can be associated with progressive destruction and disappearance of segments of the intrahepatic biliary tree.",
"   </p>",
"   <p>",
"    Because ductopenia primarily involves the interlobular bile ducts, it has been referred to as \"small-duct damage\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/1\">",
"     1",
"    </a>",
"    ]. It is considered to be present when there is loss of interlobular bile ducts in more than 50 percent of small portal tracts provided that the pathological specimen contains at least 10 portal tracts (",
"    <a class=\"graphic graphic_picture graphicRef79064 \" href=\"UTD.htm?11/43/11960\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF INTRAHEPATIC BILE DUCT INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary homeostasis exists as a balance between cell death and regeneration. Liver stem cells from the canal of Hering are the likely source of new biliary cells, a process regulated via Bcl-2 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"     2",
"    </a>",
"    ]. Bax, an apoptosis promoter, and Bcl-2, which regulates apoptosis, are both expressed on bile duct cells. However, Bax is expressed along the entire biliary tree whereas Bcl-2 appears to be limited to bile ductules and interlobular bile ducts.",
"   </p>",
"   <p>",
"    Biliary apoptosis is implicated in the pathogenesis of multiple cholangiopathies, and may actually be underappreciated due to the difficulty in accurately identifying apoptotic biliary cells in H&amp;E-stained specimens. Several mechanisms have been implicated as the initiation event in pathologic biliary apoptosis, including:",
"    <span class=\"nowrap\">",
"     Fas/FasL,",
"    </span>",
"    Perforin and granzyme B, THF-alpha, oxidative stress, and downregulation of Bcl-2.",
"   </p>",
"   <p>",
"    Bile duct loss may be reversible. Recovery from drug-induced ductopenia is preceded by a ductular proliferation followed by reappearance of bile ducts. However, recovery may not be possible when apoptosis exceeds the regenerative response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONGENITAL DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, ductal plate formation is an integral step in intrahepatic bile duct development. These plates are remodeled throughout fetal and neonatal development [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/6\">",
"     6",
"    </a>",
"    ]. A disturbance in this remodeling process may result in persistence of embryonic bile duct patterns, or ductal plate malformations (DPM). DPM can be grouped into two general types: atretic and fibrocystic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atretic diseases include extrahepatic bile duct atresia, and paucity of interlobular bile ducts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"       \"Causes of neonatal cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibrocystic diseases include the liver lesions in autosomal recessive polycystic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      ), congenital hepatic fibrosis, Caroli's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link\">",
"       \"Caroli disease\"",
"      </a>",
"      ), and Von Meyenburg complexes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple genetic diseases are associated with ductopenia including [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syndromic (ie, Alagille syndrome) and nonsyndromic varieties of paucity of interlobular bile ducts (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cystic fibrosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alpha-1 antitrypsin deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"       \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trihydroxycoprostanic acidemia, trisomies 17, 18, 21 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Progressive familial intrahepatic cholestasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IDIOPATHIC ADULTHOOD DUCTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic adulthood ductopenia (IAD) is a rare syndrome first described in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5\">",
"     5",
"    </a>",
"    ]. In a retrospective evaluation of 2082 cases of intrahepatic bile duct injury, 1.2 percent who could not be otherwise classified were termed IAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/8\">",
"     8",
"    </a>",
"    ]. No cause for bile duct loss is found by imaging, biopsy, or serology.",
"   </p>",
"   <p>",
"    It is likely that IAD comprises several disorders with atypical features, including: (1) late-onset nonsyndromic paucity of intrahepatic bile ducts, (2) small duct primary sclerosing cholangitis without large duct involvement and without evidence of inflammatory bowel disease, (3) nonsuppurative viral cholangitis, and (4) autoimmune cholangitis or cholangitis in autoimmune hepatitis, in the absence of the typical autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/8\">",
"     8",
"    </a>",
"    ]. Familial clustering of IAD has been described, suggesting that some patients may have genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEOPLASTIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplastic disorders have been associated with VBD syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestasis with bile duct loss is a well established but rare presentation of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .) Liver infiltration by lymphoma cells in Hodgkin lymphoma is seen in up to 50 percent of individuals in autopsy studies but it is uncommon to recognize hepatic involvement by liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/12\">",
"     12",
"    </a>",
"    ]. As the disease progresses, liver involvement becomes more frequent; in rare instances, Hodgkin lymphoma can present as ductopenic cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Liver biopsy demonstrating portal inflammation with atypical lymphoid cells and eosinophils is suggestive, even without typical Reed-Sternberg cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histiocytosis X",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histiocytosis X or Langerhans' cell histiocytosis may occasionally present with clinical features resembling primary sclerosing cholangitis. Cholangiographic changes are indistinguishable from primary sclerosing cholangitis. Periductal fibrosis with biliary cirrhosis may subsequently occur with duct loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune injury to the biliary system is involved in several diseases and may involve bile duct loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis (PBC) is the most widely recognized cause of adult ductopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the florid duct lesion is the pathognomonic biopsy finding for PBC, it is uncommonly demonstrated. More often, periductular granulomas with bile duct injury and subsequent loss is seen on pathologic specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immune cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical, biochemical, and histologic features of PBC but who do not have antimitochondrial antibodies have been referred to as having autoimmune cholangitis. Other autoimmune markers (eg, antinuclear and smooth muscle autoantibodies) are frequently present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary sclerosing cholangitis (PSC) typically involves both the intra- and extrahepatic biliary systems resulting in fibrosis and stricturing. The diagnosis is established by cholangiography. Findings on biopsy are usually nonspecific, although a classic (but uncommonly seen) finding is fibrous obliteration of small bile ducts in an \"onion skin\" pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variant of PSC (small duct PSC) is associated with normal cholangiography. Biopsy findings resemble classic large duct PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a systemic disease characterized by noncaseating granulomas. Two-thirds of patients have hepatic granulomas; however, clinical liver disease is uncommon. When granulomas are present in the portal tract, adjacent bile ducts may be injured, which may result in ductopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic graft versus host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic graft versus host disease (GvHD) is typically seen after allogenic bone marrow transplantation. Injury occurs when minor histocompatibility antigens expressed on the biliary epithelium are mismatched. Mononuclear cells react, and ultimately obstruct small interlobular bile ducts. Clinically, patients may present with signs and symptoms of cholestasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute hepatic cellular rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsuppurative cholangitis of the interlobular bile duct epithelium is one of the diagnostic histologic findings in acute hepatic rejection and can be associated with bile duct destruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37319?source=see_link\">",
"     \"Diagnosis of acute cellular rejection in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chronic hepatic cellular rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rejection is an uncommon cause of liver dysfunction after liver transplantation, occurring in less than 5 percent of cases. It is frequently preceded by a history of steroid-unresponsive acute cellular rejection. Biopsy is required for diagnosis and prominently features bile duct loss with obliterative vasculopathy. If identified early, altering immune suppression may occasionally arrest disease progression. Unfortunately, the process is often irreversible by the time it is recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infectious agents have been associated with ductopenia. Neonatal exposure to cytomegalovirus, syphilis, reovirus 3, and rubella have all been implicated in biliary paucity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Infections may also play a role in the triggering or progression of immune-mediated biliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Enteric organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct obstruction may result in bacterial colonization of the bile duct with enteric organisms, especially Escherichia coli. This can lead to ascending cholangitis and bile duct damage. If untreated and the damage is extensive, bile ducts are replaced by fibrous cords resembling PSC. Multiple organisms have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus: Cytomegalovirus (CMV) is the most common virus associated with vanishing bile duct syndrome, but generally occurs in neonates or immunocompromised hosts [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/16,22\">",
"       16,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reovirus type 3: Similar to CMV, perinatal exposure to reovirus 3 has been associated with bile duct destruction during embryonic development [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/16\">",
"       16",
"      </a>",
"      ]. Although the mechanism remains obscure, reovirus RNA has been demonstrated in the liver tissue of patients with biliary atresia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatitis C: Bile duct injury is a common pathologic finding in patients with chronic active hepatitis C virus (HCV) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/24\">",
"       24",
"      </a>",
"      ]. Fibrosing cholestatic hepatitis (FCH) with severe bile duct loss has also been reported after liver and renal transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatitis B: FCH has also been reported with recurrent hepatitis B after liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/26\">",
"       26",
"      </a>",
"      ]. However, the incidence has decreased significantly with the use of hepatitis B immunoglobulin prophylaxis and nucleos(t)ide analogues. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"       \"Liver transplantation for chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      EBV: Although uncommon, Epstein-Barr virus infection associated with bile duct loss has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cryptosporidia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium parvum is a well recognized cause of AIDS cholangiopathy. Diagnosis is made by ERCP, but is suspected in HIV-positive patients with cholestasis and low CD4 counts,",
"    <span class=\"nowrap\">",
"     &lt;100/",
"    </span>",
"    mm3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TOXINS AND DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced cholestasis is a common form of drug toxicity, causing 2 to 5 percent of hospitalized cases of jaundice and up to 20 percent of jaundice in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. Multiple mechanisms contribute to the cause of cholestasis and thus the clinical presentation may be acute or chronic with varying degrees of hepatitis and bile duct injury. Cholestasis with hepatitis is the most common clinical syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple medications have been associated with chronic cholestasis and ultimately VBDs (",
"    <a class=\"graphic graphic_table graphicRef57682 \" href=\"UTD.htm?34/0/34828\">",
"     table 1",
"    </a>",
"    ). Patients generally present with acute cholestasis associated with bile duct injury. The injury resolves following drug discontinuation in most patients (although it may require many weeks). In a minority, cholestasis persists for many months despite having discontinued the offending agent; such cases have been associated with VBDs. Biochemical tests of liver function may ultimately improve or normalize (and jaundice resolve) but progressive bile duct loss can lead to secondary cirrhosis, liver failure, and death or transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ISCHEMIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biliary epithelium receives its blood supply exclusively from the hepatic artery, thus any disruption in this blood flow can result in ischemic necrosis and resultant ductopenia. This can be a serious complication especially after liver transplantation, and often leads to retransplantation or biliary strictures and abscesses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and course are highly variable, reflecting the varied underlying causes. Disease onset can be rapid, as in acute cellular rejection, or gradual, as is typical for primary biliary cirrhosis.",
"   </p>",
"   <p>",
"    Most patients are identified either by abnormal liver chemistries or clinical complaints. Symptoms may reflect specific features of the underlying disease process, although more general constitutional complaints are common, and include fatigue, anorexia, abdominal pain, and weight loss. Patients frequently complain of pruritus and, when disease is severe and prolonged, can experience typical manifestations of cholestasis such as gallstone formation, hyperlipidemia, malabsorption, xanthelasmas, and fat soluble vitamin deficiencies. Patients with progressive disease leading to cirrhosis can develop complications related to portal hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is established by liver biopsy in the appropriate clinical setting. Evaluation should include imaging tests to exclude extrahepatic biliary obstruction and appropriate serologic evaluation when there is suspicion for particular clinical diagnoses (eg, AMA in patients suspected of having PBC). A careful history including all recent prescription and nonprescription drug use is essential, since drug-induced cholestasis is common and drug withdrawal is essential. Idiopathic adulthood ductopenia is present in adults with otherwise unexplained ductopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrahepatic biliary obstruction should be excluded via MRCP or ERCP. Because the disease is characterized by small duct injury, imaging tests are generally less helpful than liver biopsy for establishing the diagnosis. Cholangiography is usually normal until extensive fibrosis from secondary biliary cirrhosis develops in which the biliary tree may appeared \"pruned\", reflecting the loss of small bile ducts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation should include at the minimum serum chemistries and liver biochemical tests. Laboratory investigations generally reflect cholestasis with predominantly conjugated or direct hyperbilirubinemia and markedly elevated GGT and alkaline phosphatase, often more than 3x the upper limit of normal (ULN). A moderate aminotransferase elevation may also be present, but is rarely more than 10x ULN.",
"   </p>",
"   <p>",
"    Laboratory evaluation should also include judicious testing for specific diagnoses when there is clinical suspicion. This may include testing for viral and autoimmune hepatitis, primary biliary cirrhosis, sarcoidosis, and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy can help establish the diagnosis and evaluate the severity of liver disease. As noted above, ductopenia is considered to be present when there is loss of interlobular bile ducts in more than 50 percent of small portal tracts provided that the pathological specimen contains at least 10 portal tracts.",
"   </p>",
"   <p>",
"    Diagnostic yield can be increased by immunostaining with cytokeratin 7 and 19, both of which identify biliary elements (",
"    <a class=\"graphic graphic_picture graphicRef81586 \" href=\"UTD.htm?24/40/25220\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62914 \" href=\"UTD.htm?11/35/11828\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"     2",
"    </a>",
"    ]. Ductular proliferation may coexist with interlobular duct loss, and thus ductules must be distinguished from bile ducts. Bile ducts parallel hepatic artery branches of similar size, whereas ductular proliferation tends to appear near the limiting plate or within lobules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are generally two potential outcomes in patients with ductopenia: progressive, irreversible bile duct loss leading to extensive ductopenia and biliary cirrhosis or biliary epithelial regeneration and clinical recovery over months to years. The outcome is often unpredictable and depends on the underlying etiology of bile duct loss and available treatments. As a result, patients should be followed regularly by assessment of liver biochemical tests.",
"   </p>",
"   <p>",
"    Idiopathic ductopenia has been associated with a poor prognosis in both children and adults; up to 50 percent of patients progress to liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. However, some patients appear to progress slowly with up to 12 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/29\">",
"     29",
"    </a>",
"    ]. Hepatic decompensation tends to be slow and reflects the onset of secondary to progressive biliary obstruction and the development of secondary biliary cirrhosis. The prognosis may be better in those diagnosed when they are 40 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment choices depend mainly upon the underlying etiology of ductopenia. They may include drug withdrawal, choleretic agents, and immunosuppression. Unfortunately, there is no effective treatment for idiopathic bile duct loss. Thus, treatment frequently centers on supportive care and control of symptoms. In addition, two specific approaches have been tried: treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (a synthetic bile salt) and immunosuppression. Liver transplantation may be the only option in patients who have developed severe complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described improvement in vanishing bile duct syndrome associated with Augmentin when treated with high-dose (45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/30\">",
"     30",
"    </a>",
"    ]. Improvement in liver biochemical tests with UDCA have also been described in idiopathic adulthood ductopenia, although the impact on disease progression is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/9,31,32\">",
"     9,31,32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     Cholestyramine",
"    </a>",
"    , commonly used for pruritus, may decrease the bioavailability of UDCA secondary to intraluminal binding and thus should be given at separate intervals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple etiologies of ductopenia appear to be related to an immunologic cause providing a rationale for treatments involving immunosuppression. Unfortunately, there is little published experience [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/33\">",
"     33",
"    </a>",
"    ]. Although scattered case reports suggest some patients may improve with immune modulation, at this time the role of immunosuppression is unclear and cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with decompensation or debilitating symptoms should be considered for liver transplantation. Successful transplantation without recurrence has been described in patients with IAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21128/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vanishing bile duct syndrome refers to a group of acquired disorders resulting in progressive destruction and disappearance of the intrahepatic bile ducts and ultimately cholestasis. Ductopenia (a pathologic description) refers to the associated reduction in the number of intrahepatic bile ducts.",
"     </li>",
"     <li>",
"      Several underlying causes have been reported.",
"     </li>",
"     <li>",
"      The clinical manifestations and course are highly variable, reflecting the varied underlying causes. Disease onset can be rapid, as in acute cellular rejection, or gradual, as is typical for primary biliary cirrhosis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established by liver biopsy in the appropriate clinical setting. Evaluation should include imaging tests to exclude extrahepatic biliary obstruction and appropriate serologic evaluation when there is suspicion for particular clinical diagnoses (eg, antimitochondrial antibody in patients suspected of having primary biliary cirrhosis). A careful history including all recent prescription and nonprescription drug use is essential, since drug-induced cholestasis is common and drug withdrawal is essential. Idiopathic adulthood ductopenia is present in adults with otherwise unexplained ductopenia. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are generally two potential outcomes in patients with ductopenia: progressive, irreversible bile duct loss leading to extensive ductopenia and biliary cirrhosis (although the time course varies considerably) or biliary epithelial regeneration and clinical recovery over months to years. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment choices depend mainly upon the underlying etiology of ductopenia. They may include drug withdrawal, choleretic agents, and immunosuppression. Unfortunately, there is no proven treatment for idiopathic bile duct loss. Thus, treatment frequently centers on supportive care and control of symptoms. Transplantation may be the only option in patients who have developed severe complications. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      (a synthetic bile salt) (at a total daily dose of 13 to 15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      in most patients, although its benefit on clinical outcomes is unproven (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Most experience has been in patients with ductopenia due to Augmentin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      clavulanate) and patients with idiopathic adulthood ductopenia. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Ursodeoxycholic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are generally two potential outcomes in patients with ductopenia: progressive, irreversible bile duct loss leading to extensive ductopenia and biliary cirrhosis or biliary epithelial regeneration and clinical recovery over months to years. The outcome is often unpredictable and depends on the underlying etiology of bile duct loss and available treatments. As a result, patients should be followed regularly by assessment of liver biochemical tests. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/1\">",
"      Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000; 15:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/2\">",
"      Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg 2001; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     Moore KL. The Digestive System. In: The developing Human, clinically oriented embryology, 4th ed, WB Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/4\">",
"      Clotman F, Libbrecht L, Gresh L, et al. Hepatic artery malformations associated with a primary defect in intrahepatic bile duct development. J Hepatol 2003; 39:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/5\">",
"      Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/6\">",
"      Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26 Suppl 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/7\">",
"      Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 1993; 13:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/8\">",
"      Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998; 73:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/9\">",
"      Burak KW, Pearson DC, Swain MG, et al. Familial idiopathic adulthood ductopenia: a report of five cases in three generations. J Hepatol 2000; 32:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/10\">",
"      Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993; 17:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/11\">",
"      DeBenedet AT, Berg CL, Enfield KB, et al. A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma. Nat Clin Pract Gastroenterol Hepatol 2008; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/12\">",
"      Liangpunsakul S, Kwo P, Koukoulis GK. Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol 2002; 14:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/13\">",
"      Ozkan A, Yoruk A, Celkan T, et al. The vanishing bile duct syndrome in a child with Hodgkin disease. Med Pediatr Oncol 2001; 36:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/14\">",
"      Dich NH, Goodman ZD, Klein MA. Hepatic involvement in Hodgkin's disease. Clues to histologic diagnosis. Cancer 1989; 64:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/15\">",
"      Thompson HH, Pitt HA, Lewin KJ, Longmire WP Jr. Sclerosing cholangitis and histiocytosis X. Gut 1984; 25:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/16\">",
"      Sherlock S. The syndrome of disappearing intrahepatic bile ducts. Lancet 1987; 2:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/17\">",
"      Lacerda MA, Ludwig J, Dickson ER, et al. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/18\">",
"      Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/19\">",
"      Vierling JM, Howell CD. Disappearing bile ducts: immunologic mechanisms. Hosp Pract (Off Ed) 1990; 25:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/20\">",
"      Murphy JR, Sjogren MH, Kikendall JW, et al. Small bile duct abnormalities in sarcoidosis. J Clin Gastroenterol 1990; 12:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/21\">",
"      Burton JR Jr, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis 2006; 10:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/22\">",
"      Hindupur S, Yeung M, Shroff P, et al. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 2007; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/23\">",
"      Tyler KL, Sokol RJ, Oberhaus SM, et al. Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Hepatology 1998; 27:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/24\">",
"      Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/25\">",
"      Delladetsima JK, Makris F, Psichogiou M, et al. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver 2001; 21:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/26\">",
"      Jung S, Lee HC, Han JM, et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol 2002; 17:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/27\">",
"      Kikuchi K, Miyakawa H, Abe K, et al. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci 2000; 45:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/28\">",
"      Levy C, Lindor KD. Drug-induced cholestasis. Clin Liver Dis 2003; 7:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/29\">",
"      Moreno A, Carre&ntilde;o V, Cano A, Gonz&aacute;lez C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997; 336:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/30\">",
"      Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/31\">",
"      Smith LA, Ignacio JR, Winesett MP, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005; 41:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/32\">",
"      O'Brien CB, Shields DS, Saul SH, Reddy KR. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996; 91:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/33\">",
"      Okan G, Yaylaci S, Peker O, et al. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 2008; 14:4697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21128/abstract/34\">",
"      Rios R, Herrero JI, Quiroga J, et al. Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. Dig Dis Sci 2001; 46:1420.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3595 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21128=[""].join("\n");
var outline_f20_40_21128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Embryology and development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY OF INTRAHEPATIC BILE DUCT INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONGENITAL DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IDIOPATHIC ADULTHOOD DUCTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEOPLASTIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histiocytosis X",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNOLOGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immune cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic graft versus host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute hepatic cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chronic hepatic cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Enteric organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cryptosporidia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TOXINS AND DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ISCHEMIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3595|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/43/11960\" title=\"picture 1\">",
"      H E no duct portal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/40/25220\" title=\"picture 2\">",
"      Low cytokeratin stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/35/11828\" title=\"picture 3\">",
"      High cytokeratin stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/0/34828\" title=\"table 1\">",
"      Drugs causing cholestasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=related_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37319?source=related_link\">",
"      Diagnosis of acute cellular rejection in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21129="Clinical features and diagnosis of urinary tract infections in infants and children older than one month";
var content_f20_40_21129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Nader Shaikh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Alejandro Hoberman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21129/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/40/21129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTI) are a common and important clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal disease. Although children with pyelonephritis tend to present with fever, it is often difficult on clinical grounds to distinguish cystitis from pyelonephritis, particularly in young children (those younger than two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, we have defined UTI broadly here without attempting to distinguish cystitis from pyelonephritis. Acute cystitis in older children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link\">",
"     \"Acute cystitis in children older than two years and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of UTI in children will be discussed here. The epidemiology, risk factors, and management of UTI in children and UTI in newborns (younger than one month of age) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTI) may present with nonspecific symptoms and signs, particularly in infants and young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Younger children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of the diagnostic accuracy of the symptoms and signs of UTI in children younger than two years, the following symptoms and signs were the most helpful in identifying children with UTI (",
"    <a class=\"graphic graphic_table graphicRef69441 \" href=\"UTD.htm?40/0/40973\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of UTI (likelihood ratio [LR] 2.3)",
"     </li>",
"     <li>",
"      Temperature &gt;40&ordm;C (LR 3.2)",
"     </li>",
"     <li>",
"      Suprapubic tenderness (summary LR 4.4)",
"     </li>",
"     <li>",
"      Lack of circumcision (summary LR 2.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combinations of signs and symptoms were more useful than individual signs for identifying children with and without UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature &gt;39&ordm;C for &ge;48 hours in absence of another source for fever (LR 4.0)",
"     </li>",
"     <li>",
"      Temperature &lt;39&ordm;C, presence of another source for fever (LR 0.37)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Likelihood ratios are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluating diagnostic tests\", section on 'What are the positive and negative likelihood ratios?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fever",
"      </strong>",
"      &ndash; Several prospective studies have shown that infants and children younger than two years can present with fever as the sole manifestation of UTI [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The prevalence of UTI is greater among infants and young children with maximum temperatures &ge;39&ordm;C than in those with lesser degrees of fever (16 versus 7 percent for infants &le;60 days, and 4 versus 2 percent for children &lt;2 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"       \"Epidemiology and risk factors for urinary tract infections in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The presence of another potential source of fever (upper respiratory tract infection, acute otitis media, acute gastroenteritis) does not rule out the possibility of UTI. In studies of UTI in young children who presented to the emergency department with fever, the prevalence of UTI in children with and without another potential source of fever on examination ranged from 2 to 3 percent and 6 to 8 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/4,6\">",
"       4,6",
"      </a>",
"      ]. This highlights the importance of obtaining urine cultures in febrile infants and young children without a definite source for fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other symptoms",
"      </strong>",
"      &ndash; Less common symptoms of UTI in infants include conjugated hyperbilirubinemia (in those &lt;28 days), irritability, poor feeding, or failure to thrive [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"       \"Urinary tract infections in newborns\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Parental reporting of foul-smelling urine or the presence of gastrointestinal symptoms (vomiting, diarrhea, and poor feeding) is not helpful in diagnosing UTI [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2,8,9\">",
"       2,8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of UTI in older children may include fever, urinary symptoms (dysuria, urgency, frequency, incontinence, macroscopic hematuria), and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The constellation of fever, chills, and flank pain is suggestive of pyelonephritis in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, older children may present with short stature, poor weight gain, or hypertension (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) secondary to renal scarring from unrecognized UTI earlier in childhood&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/13\">",
"     13",
"    </a>",
"    ]. Suprapubic tenderness and costovertebral angle tenderness may be present on examination of older children with UTI.",
"   </p>",
"   <p>",
"    In a meta-analysis of the diagnostic accuracy of the symptoms and signs of UTI in verbal children, the following symptoms and signs were the most helpful in identifying children with UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain (LR 6.3)",
"     </li>",
"     <li>",
"      Back pain (LR 3.6)",
"     </li>",
"     <li>",
"      Dysuria, frequency, or both (LR 2.2)",
"     </li>",
"     <li>",
"      New-onset urinary incontinence (LR 4.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Likelihood ratios are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluating diagnostic tests\", section on 'What are the positive and negative likelihood ratios?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with urinary tract infection (UTI) symptoms should be evaluated promptly. Prompt recognition and treatment of UTI is an important factor in the prevention of renal scarring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\", section on 'Risk factors for renal scarring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of the acute illness should include documentation of the height and duration of fever, urinary symptoms (dysuria, frequency, urgency, incontinence), abdominal pain, suprapubic discomfort, back pain, vomiting, recent illnesses, antibiotics administered, and in females, sexual activity (if applicable).",
"   </p>",
"   <p>",
"    Information from the past medical history should include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic urinary symptoms &ndash; Incontinence, lack of proper stream, frequency, urgency, withholding maneuvers",
"     </li>",
"     <li>",
"      Chronic constipation",
"     </li>",
"     <li>",
"      Previous UTI",
"     </li>",
"     <li>",
"      Vesicoureteral reflux (VUR)",
"     </li>",
"     <li>",
"      Previous undiagnosed febrile illnesses",
"     </li>",
"     <li>",
"      Family history of frequent UTI, VUR, and other genitourinary abnormalities",
"     </li>",
"     <li>",
"      Antenatally diagnosed renal abnormality",
"     </li>",
"     <li>",
"      Elevated blood pressure",
"     </li>",
"     <li>",
"      Poor growth",
"     </li>",
"     <li>",
"      In sexually active girls, whether barrier contraception with spermicidal agents is used (such methods predispose to UTI by altering the normal vaginal flora [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/14\">",
"       14",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination in the child with suspected UTI include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of blood pressure and temperature",
"     </li>",
"     <li>",
"      Growth parameters (poor weight gain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      failure to thrive may be an indication of chronic or recurrent UTI)",
"     </li>",
"     <li>",
"      Abdominal examination for tenderness or mass (eg, enlarged bladder or enlarged kidney secondary to urinary obstruction) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assessment of suprapubic and costovertebral tenderness",
"     </li>",
"     <li>",
"      Examination of the external genitalia for anatomic abnormalities (eg, phimosis or labial adhesions) and signs of vulvovaginitis, vaginal foreign body, sexually transmitted diseases (STDs) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link\">",
"       \"Vulvovaginal complaints in the prepubertal child\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evaluation of the lower back for signs of occult myelodysplasia (eg, midline pigmentation, lipoma, vascular lesion, sinus, tuft of hair), which may be associated with a neurogenic bladder",
"     </li>",
"     <li>",
"      Evaluation for other sources of fever (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation for the child with suspected urinary tract infection (UTI) includes obtaining a urine sample for a dipstick",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microscopic evaluation and urine culture. Pyuria and significant bacteriuria on urine culture are necessary to make the diagnosis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis of UTI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urine sample",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Decision to obtain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to obtain a urine sample for culture is best made on a case-by-case basis, taking into consideration the age, sex, circumcision status, and the presenting signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69441 \" href=\"UTD.htm?40/0/40973\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef59396 graphicRef74329 graphicRef75971 \" href=\"UTD.htm?9/36/9802\">",
"     algorithm 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other considerations include the feasibility of follow-up, parental views toward catheterization (if catheterization is necessary), potential harm of not diagnosing an episode of UTI, harm of incorrectly diagnosing UTI, cost and availability of testing, and benefits of early treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician can use the patient's demographic and clinical characteristics to estimate the probability of UTI. As an example, consider a nine-month-old, well-appearing white girl with a temperature of 39.2&ordm;C and no definite source. The clinician can inform the parents that their daughter has an approximately 1 in 5 chance of having a serious but treatable infection (",
"    <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"     table 2",
"    </a>",
"    ), and recommend that a catheterized urine specimen be obtained.",
"   </p>",
"   <p>",
"    Urine samples for urinalysis (dipstick and microscopic examination) and culture are generally indicated in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2,17-19\">",
"     2,17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Girls and uncircumcised boys younger than two years with at least one risk factor for UTI (history of UTI, temperature &gt;39&ordm;C, fever without apparent source [particularly if the child will be treated with antibiotics], ill appearance, suprapubic tenderness, fever &gt;24 hours, or nonblack race)",
"     </li>",
"     <li>",
"      Circumcised boys younger than two years with suprapubic tenderness or at least two risk factors for UTI (history of UTI, temperature &gt;39&ordm;C, fever without apparent source [particularly if the child will be treated with antibiotics], ill appearance, suprapubic tenderness, fever &gt;24 hours, or nonblack race)",
"     </li>",
"     <li>",
"      Girls and uncircumcised boys older than two years with any of the following urinary symptoms: abdominal pain, back pain, dysuria, frequency, high fever, or new-onset incontinence",
"     </li>",
"     <li>",
"      Circumcised boys older than two years with multiple urinary symptoms (abdominal pain, back pain, dysuria, frequency, high fever, or new-onset incontinence)",
"     </li>",
"     <li>",
"      Febrile infants and children with abnormalities of the urinary tract or family history of urinary tract disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     How to obtain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheterization or suprapubic aspiration is the preferred method of urine collection for dipstick, microscopic examination, and culture of the urine in infants and young children who are not toilet-trained. Clean catch is the preferred method of collection in toilet-trained children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"     \"Urine collection techniques in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All urine specimens should be examined as soon as possible after collection. A delay of even a few hours increases both the false-positive and false-negative rates substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally suggest catheterized urine samples for children who are not toilet-trained; the sensitivity and specificity of catheterized specimens for urine culture are 95 and 99 percent, respectively, when compared with suprapubic specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/20\">",
"     20",
"    </a>",
"    ]. Nonetheless, suprapubic aspiration is a relatively straightforward procedure, and complications are rare. We specifically recommend a suprapubic aspirate when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Catheterization is not feasible (eg, severe phimosis or penile adhesions in boys; labial adhesions in girls)",
"     </li>",
"     <li>",
"      Results from a catheterized specimen are inconclusive (eg, repeated contaminated specimen or repeated low colony counts)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that urine obtained in a sterile bag",
"    <strong>",
"     not",
"    </strong>",
"    be used for culture. Up to 85 percent of positive cultures from bag urine specimens represent false-positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/20\">",
"     20",
"    </a>",
"    ]; results of urine cultures from bag specimens are useful only if they are negative. The high false-positive rate of bag specimens can lead to unnecessary and even harmful interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"     \"Urine collection techniques in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also suggest that bag urine specimens not be used for dipstick or microscopic analysis. However, others suggest that bag urine samples can be used as a first step to determine whether a catheterized urine sample should be obtained for culture in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. This approach is not recommended in ill-appearing patients or in patients who require antibiotics immediately after the urine specimen is collected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rapidly available tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of the various diagnostic tests in predicting significant bacteriuria on culture has been the subject of two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The sensitivity, specificity, and likelihood ratios of rapidly available tests to diagnose UTI in children are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dipstick analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dipstick tests are convenient, inexpensive, and require little training for proper usage; they may be the only test available in some settings. However, they will likely miss some children with UTI (at best they are 88 percent sensitive) (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/23\">",
"     23",
"    </a>",
"    ]. Because the sensitivity of dipstick analysis is less than 100 percent, we suggest that a urine culture be obtained in children with suspected UTI who have a negative dipstick test. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Urine culture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocyte esterase &ndash; The presence of leukocyte esterase on dipstick analysis is suggestive of UTI. However, a positive leukocyte esterase test does not always signal a true UTI because WBCs may be present in the urine in other conditions (eg, Kawasaki disease). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pyuria'",
"      </a>",
"      below.). In a two-year-old circumcised boy with a positive leukocyte esterase test, for example, the probability of UTI is &lt;4 percent, based upon the following calculation:",
"      <br/>",
"      <br/>",
"      Post-test probability = Pretest probability x the positive likelihood ratio",
"      <br/>",
"      <br/>",
"      In this example, the pretest probability is &lt;1 percent (",
"      <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"       table 2",
"      </a>",
"      ) and the positive likelihood ratio is 4 (",
"      <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"       table 3",
"      </a>",
"      ), which results in a post-test probability of &lt;4 percent. Likelihood ratios are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H15#H15\">",
"       \"Evaluating diagnostic tests\", section on 'What are the positive and negative likelihood ratios?'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nitrite &ndash; A child with a positive nitrite test is likely to have a UTI. The nitrite test is highly specific, with a low false-positive rate (",
"      <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"       table 3",
"      </a>",
"      ). However, false-negative tests are common, because urine needs to remain in the bladder for at least four hours to accumulate a detectable amount of nitrite. Thus, a negative nitrite test does not exclude a UTI (",
"      <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Microscopic exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic examination requires more equipment and training than dipstick tests. In standard microscopy, a centrifuged sample of unstained urine is examined for white blood cells (WBC) and bacteria. When performed in this way, pyuria is defined as &ge;5",
"    <span class=\"nowrap\">",
"     WBC/high",
"    </span>",
"    power field (hpf) and bacteriuria as the presence of any bacteria per hpf. The sensitivity, specificity, and likelihood ratios are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"     table 3",
"    </a>",
"    ). Because the sensitivity of the standard microscopic examination conducted using a centrifuged urine specimen is at best 81 percent, we suggest that a urine culture be obtained in children with suspected UTI who have a negative standard microscopic examination. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Urine culture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The accuracy of microscopic analysis is improved by using [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An uncentrifuged specimen",
"     </li>",
"     <li>",
"      A hemocytometer (results reported as",
"      <span class=\"nowrap\">",
"       WBC/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      A Gram-stained smear",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of a catheterized urine sample using these three techniques, which are available at some academic centers, has been called an \"enhanced urinalysis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/24\">",
"     24",
"    </a>",
"    ]. When using the enhanced urinalysis, pyuria is defined by &ge;10",
"    <span class=\"nowrap\">",
"     WBC/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and bacteriuria by the presence of any bacteria per 10 oil immersion fields of a Gram-stained smear.",
"   </p>",
"   <p>",
"    In young children in whom the prompt diagnosis and treatment of UTI are paramount, the enhanced urinalysis offers the best combination of sensitivity and specificity (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. However, enhanced urinalysis is not available in many outpatient settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urine culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine culture is the gold standard for the diagnosis of UTI. We suggest that urine culture be performed routinely for all children in whom a sample for urinalysis or dipstick is collected. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Decision to obtain'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Urine obtained for culture should be processed as soon as possible after collection. A delay of even a few hours increases both the false-positive and false-negative rates substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory tests are not particularly helpful in the diagnosis of UTI and are not routinely necessary in children with suspected UTI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markers of inflammation &ndash; We do not routinely obtain markers of inflammation in the evaluation of children with suspected UTI. Elevated peripheral WBC, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) are indicators of an acute inflammatory process. Although some studies have shown that these markers are associated with upper tract infection, because of their low sensitivity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      specificity, these tests do not reliably differentiate between children with cystitis and children with pyelonephritis.",
"      <br/>",
"      <br/>",
"      As an example, approximately 30 percent of children with a normal CRP have pyelonephritis by 99m technetium-dimercaptosuccinic acid (DMSA) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/26\">",
"       26",
"      </a>",
"      ]. Similarly, although PCT appears to be the most accurate marker of pyelonephritis to date, its predictive value is too low for use as a screening test. A meta-analysis of children with culture-proven UTI examined the sensitivity and specificity of PCT in differentiating cystitis from pyelonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/27\">",
"       27",
"      </a>",
"      ]. The 10 studies included in this meta-analysis were relatively small and suffered from important methodological limitations. There was significant heterogeneity in the results; sensitivity of PCT ranged from 60 to 100 percent, and specificity ranged from 25 to 98 percent. Until larger, more definitive studies are conducted, measurement of PCT does not appear to be clinically indicated.",
"     </li>",
"     <li>",
"      Serum creatinine &ndash; Measurement of serum creatinine is not routinely necessary in children with suspected UTI. However, we suggest that serum creatinine be measured in children with a history of multiple UTI and suspected renal involvement.",
"     </li>",
"     <li>",
"      Blood culture &ndash; Bacteremia occurs in 4 to 9 percent of infants with UTI [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/13,28,29\">",
"       13,28,29",
"      </a>",
"      ]. Fever in bacteremic infants with UTI persists, on average, one day longer than in non-bacteremic infants with UTI [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/30\">",
"       30",
"      </a>",
"      ]. However, a positive blood culture does not alter management in the vast majority of children because usually the same organism is isolated from the blood and urine.",
"      <br/>",
"      <br/>",
"      Accordingly, we do not routinely obtain a blood culture in children older than two months of age who have UTI and do not require blood culture for other reasons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lumbar puncture &ndash; Lumbar puncture generally is not warranted in infants and children older than one month with UTI. Lumbar puncture in infants younger than one month with UTI is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"       \"Urinary tract infections in newborns\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF UTI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992419017\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative urine culture is the standard test for the diagnosis of UTI. UTI is best defined as",
"    <strong>",
"     significant bacteriuria",
"    </strong>",
"    in a patient with",
"    <strong>",
"     pyuria",
"    </strong>",
"    (ie, evidence of an inflammatory response).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Significant bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;What constitutes significant bacteriuria depends upon the method of collection and the identification of the isolated organism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    spp, coagulase-negative staphylococci, and",
"    <em>",
"     Corynebacterium",
"    </em>",
"    spp are not considered clinically relevant uropathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clean catch&nbsp;sample &ndash; We define significant bacteriuria from a clean catch urine specimen in children as growth of &ge;100,000 colony forming units",
"      <span class=\"nowrap\">",
"       (CFU)/mL",
"      </span>",
"      of a single uropathogenic bacteria. This is the same as the standard definition for significant bacteriuria on clean catch specimens in adults, which is based upon studies from the 1950s [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catheter sample &ndash; We define significant bacteriuria from catheterized specimens in children as growth of &ge;50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      of a single uropathogenic bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/19\">",
"       19",
"      </a>",
"      ]. In a prospective study of febrile children &lt;24 months of age, catheterized urine samples with 10,000 to 50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      were more likely than specimens with &ge;50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      to yield gram-positive organisms (excluding enterococci) or mixed organisms than those with &ge;50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      (65 versus 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We suggest that children who have growth of 10,000 to 50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      from an initial catheterized specimen have a repeat urine culture. We consider such children to have UTI if the second culture grows &ge;10,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      and pyuria is present on dipstick or microscopic urinalysis.",
"     </li>",
"     <li>",
"      Suprapubic sample &ndash; We define significant bacteriuria from suprapubic aspiration specimens as the growth of any uropathogenic bacteria (the growth of one colony on the plate is equivalent to 1000",
"      <span class=\"nowrap\">",
"       CFU/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     False negatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;False-negative results in children with UTI (eg, failure to meet the definitions of significant bacteriuria described above) may occur under the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/6,32\">",
"     6,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A bacteriostatic antimicrobial agent is present in the urine",
"     </li>",
"     <li>",
"      Rapid rate of urine flow with reduced incubation time",
"     </li>",
"     <li>",
"      Obstruction of the ureter that interferes with the discharge of bacteria into the bladder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such cases, when the urine culture will not provide definitive results, renal scintigraphy may be helpful in establishing the diagnosis of acute pyelonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Renal scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of WBC in the urine is not specific for UTI. However, true UTI without pyuria (eg, positive leukocyte esterase on dipstick analysis, &ge;5",
"    <span class=\"nowrap\">",
"     WBC/hpf",
"    </span>",
"    with standardized microscopy, or &ge;10",
"    <span class=\"nowrap\">",
"     WBC/mm3",
"    </span>",
"    on a hemocytometer with an enhanced urinalysis) is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of pyuria in the presence of significant bacteriuria may occur under the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early in the course of UTI (before the local inflammatory response develops)",
"     </li>",
"     <li>",
"      Colonization of the urinary tract (eg, asymptomatic bacteriuria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children who are suspected of having UTI but in whom pyuria is not detected on dipstick or microscopic analysis, repeating the urinalysis and urine culture can help to distinguish between early infection and colonization (",
"    <a class=\"graphic graphic_algorithm graphicRef55592 \" href=\"UTD.htm?37/28/38348\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of pyuria and bacteriuria on the second sample is suggestive of UTI",
"     </li>",
"     <li>",
"      The absence of pyuria and bacteriuria on the second sample is suggestive of bacterial contamination of the initial sample",
"     </li>",
"     <li>",
"      Bacteriuria without pyuria on the second sample is suggestive of asymptomatic bacteriuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Asymptomatic bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic bacteriuria (ie, colonization of the urinary tract with bacteria in the absence of inflammation) occurs in 1 to 3 percent of infants and preschool age children, and approximately 1 percent of older children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The bacteria tend to be of low virulence and are easily eliminated by antibiotics. However, in most children, asymptomatic bacteriuria resolves spontaneously without causing renal scarring, decreased filtration rate, or interfering with renal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend antibiotic treatment of asymptomatic bacteria in children. A meta-analysis of three randomized trials found the evidence insufficient to determine the risks and benefits, but concluded that antibiotic therapy is unlikely to benefit children in the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in a child with suspected urinary tract infection (UTI) depends upon the presenting symptoms and signs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of a well-appearing infant who has fever without a definite source is extensive, but most commonly includes UTI and occult bacteremia. In children vaccinated against",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      and",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , the probability of UTI (7 percent) is much higher than the probability of occult bacteremia (&lt;1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21129/abstract/2,40-42\">",
"       2,40-42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary symptoms (eg, urgency, frequency, dysuria) and bacteriuria may be caused by nonspecific vulvovaginitis, irritant (or chemical) urethritis (eg, bubble baths), urinary calculi, urethritis secondary to a sexually transmitted disease (STD) (particularly Chlamydia), and vaginal foreign body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link\">",
"       \"Vulvovaginal complaints in the prepubertal child\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"       \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with group A streptococcal infection, appendicitis, and Kawasaki disease may present with fever, abdominal pain, and pyuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link\">",
"       \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bowel and bladder dysfunction is a frequently overlooked diagnosis in children with urinary symptoms and a negative urine culture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology and risk factors for urinary tract infections in children\", section on 'Bowel and bladder dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever may be the only sign of urinary tract infection (UTI) in infants and young children. Older children may have urinary symptoms (",
"      <a class=\"graphic graphic_table graphicRef69441 \" href=\"UTD.htm?40/0/40973\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history in a child with suspected UTI include features of the acute illness (eg, fever, presence of urinary symptoms) and risk factors for UTI (",
"      <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"       \"Epidemiology and risk factors for urinary tract infections in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The examination of the child with suspected UTI should include measurement of blood pressure, temperature, and growth parameters; abdominal examination for tenderness or mass; assessment of suprapubic and costovertebral tenderness; examination of the external genitalia; evaluation of the lower back for signs of occult myelodysplasia; and a search for other sources of fever. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation for the child with suspected UTI includes obtaining a urine sample for a dipstick",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      microscopic evaluation and urine culture (",
"      <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"       table 3",
"      </a>",
"      ). Urine culture is necessary to make the diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that urine samples be obtained for urinalysis and culture in the following patients (",
"      <a class=\"graphic graphic_algorithm graphicRef59396 graphicRef74329 graphicRef75971 \" href=\"UTD.htm?9/36/9802\">",
"       algorithm 1A-C",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H10\">",
"       'Decision to obtain'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Girls and uncircumcised boys younger than two years with at least one risk factor for UTI (history of UTI, temperature &gt;39&ordm;C, fever without apparent source [particularly if the child will be treated with antibiotics], ill appearance, suprapubic tenderness, fever &gt;24 hours, or nonblack race).",
"     </li>",
"     <li>",
"      Circumcised boys younger than two years with suprapubic tenderness or at least two risk factors for UTI (history of UTI, temperature &gt;39&ordm;C, fever without apparent source, ill appearance, suprapubic tenderness, fever &gt;24 hours, or nonblack race).",
"     </li>",
"     <li>",
"      Girls and uncircumcised boys older than two years with any of the following urinary or abdominal symptoms (abdominal pain, back pain, dysuria, frequency, high fever, or new-onset incontinence).",
"     </li>",
"     <li>",
"      Circumcised boys older than two years with multiple urinary symptoms (abdominal pain, back pain, dysuria, frequency, high fever, or new-onset incontinence).",
"     </li>",
"     <li>",
"      Febrile infants and children with abnormalities of the urinary tract or family history of urinary tract disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheterization is the preferred method of urine collection for infants and young children who are not toilet-trained. Clean catch is the preferred method of collection for toilet-trained children. We recommend that urine obtained in a sterile bag not be used for culture. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'How to obtain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that urine culture be performed routinely for all children in whom a sample for urinalysis or dipstick is collected. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Urine culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of UTI requires laboratory confirmation. UTI is best defined as significant bacteriuria in a patient with pyuria on dipstick or microscopic urinalysis. We define significant bacteriuria as recovery of &ge;100,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      of a uropathogen from a clean catch specimen, &ge;50,000",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      of a uropathogen from a catheterized specimen, and any uropathogenic bacteria from a suprapubic aspirate. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Significant bacteriuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/1\">",
"      Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/2\">",
"      Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/3\">",
"      Hoberman A, Chao HP, Keller DM, et al. Prevalence of urinary tract infection in febrile infants. J Pediatr 1993; 123:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/4\">",
"      Shaw KN, Gorelick M, McGowan KL, et al. Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics 1998; 102:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/5\">",
"      Zorc JJ, Levine DA, Platt SL, et al. Clinical and demographic factors associated with urinary tract infection in young febrile infants. Pediatrics 2005; 116:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/6\">",
"      Hoberman A, Wald ER. Urinary tract infections in young febrile children. Pediatr Infect Dis J 1997; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/7\">",
"      Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/8\">",
"      Struthers S, Scanlon J, Parker K, et al. Parental reporting of smelly urine and urinary tract infection. Arch Dis Child 2003; 88:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/9\">",
"      Gauthier M, Gouin S, Phan V, Gravel J. Association of malodorous urine with urinary tract infection in children aged 1 to 36 months. Pediatrics 2012; 129:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/10\">",
"      Winberg J, Andersen HJ, Bergstr&ouml;m T, et al. Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr Scand Suppl 1974; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/11\">",
"      Majd M, Rushton HG, Jantausch B, Wiedermann BL. Relationship among vesicoureteral reflux, P-fimbriated Escherichia coli, and acute pyelonephritis in children with febrile urinary tract infection. J Pediatr 1991; 119:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/12\">",
"      SMELLIE JM, HODSON CJ, EDWARDS D, NORMAND IC. CLINICAL AND RADIOLOGICAL FEATURES OF URINARY INFECTION IN CHILDHOOD. Br Med J 1964; 2:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/13\">",
"      Smellie JM, Poulton A, Prescod NP. Retrospective study of children with renal scarring associated with reflux and urinary infection. BMJ 1994; 308:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/14\">",
"      Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000; 343:992.",
"     </a>",
"    </li>",
"    <li>",
"     Wald ER. Cystitis and pyelonephritis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.554.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/16\">",
"      Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/17\">",
"      Wald ER. To bag or not to bag. J Pediatr 2005; 147:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/18\">",
"      Shaw KN, Gorelick MH. Urinary tract infection in the pediatric patient. Pediatr Clin North Am 1999; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/19\">",
"      Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011; 128:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/20\">",
"      Finnell SM, Carroll AE, Downs SM, Subcommittee on Urinary Tract Infection. Technical report&mdash;Diagnosis and management of an initial UTI in febrile infants and young children. Pediatrics 2011; 128:e749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/21\">",
"      Al-Orifi F, McGillivray D, Tange S, Kramer MS. Urine culture from bag specimens in young children: are the risks too high? J Pediatr 2000; 137:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/22\">",
"      Huicho L, Campos-Sanchez M, Alamo C. Metaanalysis of urine screening tests for determining the risk of urinary tract infection in children. Pediatr Infect Dis J 2002; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/23\">",
"      Gorelick MH, Shaw KN. Screening tests for urinary tract infection in children: A meta-analysis. Pediatrics 1999; 104:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/24\">",
"      Hoberman A, Wald ER, Penchansky L, et al. Enhanced urinalysis as a screening test for urinary tract infection. Pediatrics 1993; 91:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/25\">",
"      Herr SM, Wald ER, Pitetti RD, Choi SS. Enhanced urinalysis improves identification of febrile infants ages 60 days and younger at low risk for serious bacterial illness. Pediatrics 2001; 108:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/26\">",
"      Biggi A, Dardanelli L, Pomero G, et al. Acute renal cortical scintigraphy in children with a first urinary tract infection. Pediatr Nephrol 2001; 16:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/27\">",
"      Mantadakis E, Plessa E, Vouloumanou EK, et al. Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies. J Pediatr 2009; 155:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/28\">",
"      Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999; 104:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/29\">",
"      Bachur R, Caputo GL. Bacteremia and meningitis among infants with urinary tract infections. Pediatr Emerg Care 1995; 11:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/30\">",
"      Honkinen O, Jahnukainen T, Mertsola J, et al. Bacteremic urinary tract infection in children. Pediatr Infect Dis J 2000; 19:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/31\">",
"      KASS EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 1956; 69:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/32\">",
"      Hoberman A, Wald ER, Reynolds EA, et al. Pyuria and bacteriuria in urine specimens obtained by catheter from young children with fever. J Pediatr 1994; 124:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/33\">",
"      Hoberman A, Wald ER. Treatment of urinary tract infections. Pediatr Ann 1999; 28:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/34\">",
"      Linshaw M. Asymptomatic bacteriuria and vesicoureteral reflux in children. Kidney Int 1996; 50:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/35\">",
"      Wettergren B, Jodal U, Jonasson G. Epidemiology of bacteriuria during the first year of life. Acta Paediatr Scand 1985; 74:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/36\">",
"      Lindberg U, Claesson I, Hanson LA, Jodal U. Asymptomatic bacteriuria in schoolgirls. VIII. Clinical course during a 3-year follow-up. J Pediatr 1978; 92:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/37\">",
"      Sequelae of covert bacteriuria in schoolgirls. A four-year follow-up study. Lancet 1978; 1:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/38\">",
"      Hansson S, Martinell J, Stokland E, Jodal U. The natural history of bacteriuria in childhood. Infect Dis Clin North Am 1997; 11:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/39\">",
"      Fitzgerald A, Mori R, Lakhanpaul M. Interventions for covert bacteriuria in children. Cochrane Database Syst Rev 2012; 2:CD006943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/40\">",
"      Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 2008; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/41\">",
"      Hsiao AL, Chen L, Baker MD. Incidence and predictors of serious bacterial infections among 57- to 180-day-old infants. Pediatrics 2006; 117:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21129/abstract/42\">",
"      Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med 2004; 158:671.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5990 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21129=[""].join("\n");
var outline_f20_40_21129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Younger children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urine sample",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Decision to obtain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - How to obtain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rapidly available tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dipstick analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Microscopic exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urine culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS OF UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992419017\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Significant bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - False negatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pyuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5990|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/6/7268\" title=\"algorithm 1A\">",
"      Male infants UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/49/43795\" title=\"algorithm 1B\">",
"      Female infants UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/16/39168\" title=\"algorithm 1C\">",
"      Verbal children UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/28/38348\" title=\"algorithm 2\">",
"      Suspected UTI without pyuria algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/0/40973\" title=\"table 1\">",
"      Dx accuracy UTI sx children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/16/269\" title=\"table 2\">",
"      Prevalence of UTI in febrile infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28109\" title=\"table 3\">",
"      Tests to diagnose UTI in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=related_link\">",
"      Acute cystitis in children older than two years and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=related_link\">",
"      Epidemiology and risk factors for urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=related_link\">",
"      Patient information: Urinary tract infections in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=related_link\">",
"      Urine collection techniques in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21130="Rituximab and other B cell targeted therapies for rheumatoid arthritis";
var content_f20_40_21130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21130/contributors\">",
"     Maria J Leandro, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21130/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/40/21130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/40/21130/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/40/21130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell targeted therapy for rheumatoid arthritis (RA) was developed with the objective of removing B cell clones responsible for the production of pathogenic autoantibodies. A specific objective was to induce sustained remission from short-term B cell depletion, based on the hypothesis that autoantibodies could not only produce tissue pathology but might be expected to drive their own production through a vicious cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/1\">",
"     1",
"    </a>",
"    ]. Although this has yet to be achieved, B cell depletion therapy has been found to have a major impact on RA in the short term.",
"   </p>",
"   <p>",
"    Interest in B cell depletion was fueled by new evidence for the potential pathogenic role of immune complexes in RA. The beneficial effects of anti-tumor necrosis factor (TNF) agents highlighted the importance of the production of TNF by macrophages within the joint. The association of RA with MHC class II allotype implicated a CD4-T cell dependent process, but it was not clear whether this involved T cell help for antibody production or a direct effect of T cells on macrophages. Work on macrophage Fc-gamma receptors showed that TNF production in synovium might be explained by the binding of small IgG-based immune complexes to these receptors rather than by the action of cytokines from antigen&ndash;stimulated T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/2\">",
"     2",
"    </a>",
"    ]. The evidence for this remains conflicting.",
"   </p>",
"   <p>",
"    Central to the concept of B cell depletion therapy was the idea that pathogenic B cell clones and their autoantibody products might be engaged in a vicious cycle of self-perpetuation that does not require T cell autoreactivity. The interruption of such a cycle would restore immune tolerance and, therefore, might allow sustained benefit. This objective has been partially achieved. Although the majority of patients relapse within the first eighteen months after treatment, a small number of patients remain well for longer (occasionally up to four years) after a single course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B cell depletion has been associated with clinical improvement in many (but not all) conditions associated with autoantibody production. In contrast, a variety of conditions that are seronegative conditions (eg, psoriasis) does not appear to respond to this intervention. Nevertheless, modest improvement has been reported in seronegative RA, and there remains a possibility that, in at least some cases, a therapeutic effect is achieved through B cell functions involved in supporting T cell effector mechanisms.",
"   </p>",
"   <p>",
"    Antigen presentation by B cells and cytokine-mediated interactions with stromal and accessory cells could potentially activate autoreactive T cells, although there is some doubt as to whether this is consistent with the behavior of synovial T cells in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/4\">",
"     4",
"    </a>",
"    ]. B cells are very efficient at presenting soluble antigen that has been bound by their antigen receptor (surface immunoglobulin) during the acquisition of T cell help.",
"   </p>",
"   <p>",
"    Clarification of the roles of B cells in RA is crucial to future developments in B cell targeted therapy and to the way we use this strategy. If the main role of B cells is to activate autoreactive pathogenic T cell clones through antigen presentation, one would expect patients to require continuous B cell depletion for their disease to remain under control. If autoantibodies play a key role in propagation of the disease, then achieving sustained remissions from short periods of depletion seems a much more realistic prospect. Progress so far is promising, and exploration of more potent depleting regimens or more subtle approaches to blocking signals involved in B cell proliferation is to be expected soon.",
"   </p>",
"   <p>",
"    The clinical application of B cell targeted therapies for patients with RA is presented here. Much of the discussion focuses on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , a chimeric monoclonal antibody that depletes B cells. Other B cell directed treatments that may be clinically relevant are also reviewed. The effectiveness and safety of B cell targeted therapy in other diseases, including lymphoma, and in selected autoantibody mediated disorders are discussed separately in relation to the specific disease or disorder. (See appropriate topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RITUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a B cell depleting monoclonal anti-CD20 antibody, comprised of both mouse and human portions. It has received regulatory approval in the United States for use in combination with MTX for patients with moderately or severely active RA that has not responded adequately to anti-TNF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytes of the B cell lineage undergo an orderly developmental process that includes the surface expression of CD20, a B lymphocyte-specific molecule, beginning at the pre-B cell stage. Expression of CD20 on the cell surface is lost as B cells differentiate into plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    causes B cell depletion and may do so through one or more of several antibody-dependent mechanisms, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fc receptor gamma-mediated antibody-dependent cytotoxicity",
"     </li>",
"     <li>",
"      Complement-mediated cell lysis",
"     </li>",
"     <li>",
"      Growth arrest",
"     </li>",
"     <li>",
"      B cell apoptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain which of these mechanisms is most important in the depletion of B cells in patients with RA.",
"   </p>",
"   <p>",
"    Absent CD20 protein expression on the surface of plasma cells accounts for resistance of these long-lived antibody-producing cells to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . As a consequence of plasma cell resistance, overall immunoglobulin levels usually remain within the normal range, despite profound B cell lymphopenia that persists for months following a single course of treatment. However, there are some data that levels of autoantibodies with the potential for roles in disease pathophysiology are affected by B cell depletion. Examples of this include RF in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], anti-dsDNA in systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/9\">",
"     9",
"    </a>",
"    ], and antineutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial uncontrolled studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or in combination with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , suggested a beneficial effect on the clinical manifestations of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. Subsequent clinical trials in patients with active disease despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/8,15\">",
"     8,15",
"    </a>",
"    ] or in those refractory or intolerant to anti-tumor necrosis factor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/16\">",
"     16",
"    </a>",
"    ] established the efficacy of rituximab. Several reports indicate that positive testing for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibodies predicts a greater likelihood of responsiveness to rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Major clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following two randomized trials illustrate the range of findings with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    In one trial, 161 patients with persistently active, seropositive RA on at least 10 mg of MTX per week were assigned to one of four interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      None &mdash; MTX continued, usually at the pre-trial dose",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      administration and MTX withdrawal &mdash; Rituximab (1000 mg intravenously on days 1 and 15)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      administration and MTX unchanged &mdash; Rituximab (as above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      administration and MTX withdrawal &mdash; Rituximab (as above) and cyclophosphamide (750 mg on days 3 and 17)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in all four treatment groups received concomitant glucocorticoids according to the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      100 mg intravenously on days 1, 3, 15, and 17",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      60 mg on days 2 and 4 through 7",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      30 mg on days 8 through 14",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary outcome measure was an ACR50 response. Secondary measures included the ACR20, ACR70, and EULAR moderate to good response based on the DAS28. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary end point, achieving an ACR50 or better response at six months, was noted in a significantly higher proportion of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the context of continued MTX or rituximab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with MTX withdrawal compared with those continuing to receive MTX alone. Furthermore, the proportions achieving an ACR20 and a moderate or good EULAR response were significantly higher among the groups that received any regimen including rituximab compared with the group that continued to receive MTX.",
"   </p>",
"   <p>",
"    The results can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of subjects achieving an ACR20 response at the end of six months were 38, 65, 73, and 76 percent in the control (MTX unchanged) and the three",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      groups, respectively.",
"     </li>",
"     <li>",
"      ACR50 responses at six months were noted in 13, 33, 43, and 41 percent, respectively.",
"     </li>",
"     <li>",
"      ACR70 responses were noted in 5, 15, 23, and 15 percent, respectively.",
"     </li>",
"     <li>",
"      Moderate or good responses to treatment, as assessed by the European League Against Rheumatism (EULAR) criteria, occurred in 83 to 85 percent of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      treated subjects compared with 50 percent of those receiving MTX alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second trial, known as the REFLEX trial, randomly assigned 520 patients with active RA despite treatment with both MTX and an anti-tumor necrosis factor (TNF) agent to receive two IV infusions one week apart of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (1000 mg) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/16\">",
"     16",
"    </a>",
"    ]. TNF inhibitors were discontinued in the patients who were being treated with such agents at baseline. MTX was continued at a stable dose (10 to 25",
"    <span class=\"nowrap\">",
"     mg/week).",
"    </span>",
"   </p>",
"   <p>",
"    Each infusion (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or placebo) was preceded by an IV infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (100 mg) and was followed by daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on days 2 through 7, followed by 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on days 8 through 14). Patient responses were assessed at four weekly intervals for 24 weeks.",
"   </p>",
"   <p>",
"    The principal results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients with ACR20, ACR50, and ACR70 responses was significantly greater in those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and MTX compared with those who received placebo and MTX.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ACR20 responses in 51 versus 18 percent",
"     </li>",
"     <li>",
"      ACR50 responses in 27 versus 5 percent",
"     </li>",
"     <li>",
"      ACR70 responses in 12 versus 1 percent",
"     </li>",
"     <li>",
"      EULAR moderate or good responses in 65 versus 22 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean disease activity, as measured by the DAS28, decreased significantly from baseline over the first four weeks in both groups; after four weeks the mean DAS28 rose steadily for those receiving MTX and placebo while this measure did not rise in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus MTX group during the subsequent 20 weeks.",
"     </li>",
"     <li>",
"      The difference in radiographic progression at six months (0.6 versus 1.2 point increase in total radiographic Genant-modified Sharp score, respectively) was not statistically significant. However, further follow-up of these patients showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      treatment caused a significant reduction in joint damage progression when compared with placebo at one year (1.0 versus 2.3 increase in total radiographic Genant-modified Sharp score, respectively), and at two years (1.1 versus 2.8 increase in total radiographic Genant-modified Sharp score, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient reported outcomes, including pain, fatigue, functional disability, health-related quality of life, and disease activity, showed clinically meaningful and sustained improvement following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/24\">",
"       24",
"      </a>",
"      ]. As an example, the functional disability measured by the Health Assessment Questionnaire (HAQ) Disability Index (DI) showed greater improvement in the rituximab patients beginning at week eight of the study, and the mean improvement at week 24 was greater with the addition of rituximab compared with placebo (-0.44 versus -0.07, where the minimum clinically important difference was 0.22).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two trials formed the basis for the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as a treatment for RA in patients whose disease is refractory to both MTX and TNF inhibitors. In such patients, a 2007 consensus statement suggested a threshold for disease activity of at least moderate as assessed by the 28-joint Disease Activity Score (DAS28 &ge;3.2) or the simplified Disease Activity Index (SDAI &gt;11) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    dosing regimen that received regulatory approval, 1000 mg given twice, was selected on the basis of a dose ranging study. The DANCER trial compared a regimen of rituximab 1000 mg given twice with a lower dose (500 mg given twice) in 465 patients with RA refractory to MTX alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no difference between the two groups in the proportion of patients who achieved an ACR20 response (54 and 55 percent). However, the 1000 mg regimen was associated with significant increases in the proportion of patients achieving an ACR70 response (20 versus 13 percent) or a EULAR \"good\" response (28 versus 14 percent). The use of oral glucocorticoids during the first two weeks of therapy (as used in the two other trials) did not influence efficacy results at 24 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Combination with leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    in an open-label trial in 15 patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/26\">",
"     26",
"    </a>",
"    ]. Efficacy and safety seemed to be similar to those when rituximab is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rituximab versus a second TNF inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective cohort study nestled within the Swiss Clinical Quality Management RA cohort included all 116 patients with inadequate responses to at least one TNF inhibitor who subsequently were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (50 patients) or a second TNF inhibitor (66 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/27\">",
"     27",
"    </a>",
"    ]. At six months, the mean decrease in the DAS28 was -1.61 (95% CI -1.97 to -1.25) among patients on rituximab, compared with -0.98 (95% CI -1.33 to -0.62) among those given a second TNF inhibitor.",
"   </p>",
"   <p>",
"    Further extension (to a total of 318 patients) and subgroup analysis of this study showed that switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was more effective than switching to another anti-TNF agent in patients who had failed anti-TNF because of inefficacy (either primary or secondary; 65 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/28\">",
"     28",
"    </a>",
"    ]. No significant differences were found between these two alternatives in the group of patients who had previously failed anti-TNF because of side effects (35 percent of cases). Unexpectedly, the observed efficacy of switching for both treatment options was lower in this last group of patients when compared with patients who had failed for inefficacy.",
"   </p>",
"   <p>",
"    Another report of a registry-based study compared efficacy results as measured by DAS28 at three and six months in patients who failed one or two anti-TNF agents and were switched to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or another anti-TNF agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/29\">",
"     29",
"    </a>",
"    ]. In patients who failed one anti-TNF, rituximab was as effective as and, in some cases (when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ), better than a second anti-TNF agent. In patients who had previously failed both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and a monoclonal anti-TNF, rituximab was superior to the third anti-TNF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Retreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We retreat patients six months after the first course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    if disease is still active (persistence of inflammatory symptoms, swollen joints, raised serum CRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/30\">",
"     30",
"    </a>",
"    ]. Occasional patients clearly need more than one course of treatment to achieve their maximum response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011412\">",
"    <span class=\"h4\">",
"     Retreatment of responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data that illustrate the evidence supporting the efficacy and safety of retreating patients who initially respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy are shown below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy and safety of repeated infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      have been assessed in the extension phase of three double-blind-trials cited above (including REFLEX and DANCER) that involved a total of 1039 patients; of these, 570, 191, and 40 patients received two, three, or four courses of therapy, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients eligible for repeat treatment with rituximab had a",
"      <span class=\"nowrap\">",
"       swollen/tender",
"      </span>",
"      joint count of eight or more and had relapsed at &ge;16 weeks (or 24 weeks in REFLEX) after the previous course. The criteria for repeat treatment were at least 20 percent reductions in both the swollen joint count and the tender joint count at any visit more than 16 weeks after initial therapy. Among such patients, the administration of repeat rituximab (rather than some other approach) was at the discretion of the clinician.",
"      <br/>",
"      <br/>",
"      ACR20, 50, and 70 responses, as well as DAS28 scores, were similar after the first and subsequent courses, as were adverse events other than infusion reactions, which were most often seen during the first three months. The authors concluded that patients treated with repeated courses of rituximab have sustained clinical responses with no new adverse events.",
"     </li>",
"     <li>",
"      In a pooled retrospective analysis of data from randomized trials and their extension phases (referred to above), comparison of retreatment to target (repeated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      courses from 24 weeks after previous course if DAS28 of &ge;2.6) with retreatment per demand (at clinician's discretion, but both total and swollen joint counts TJC and SJC &ge;8) showed better responses in patients retreated to target [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. No significant differences in the incidence of serious adverse events were noted between the two different groups.",
"     </li>",
"     <li>",
"      Pooled safety data from a six-year follow-up of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      trials included a total of 2578 patients who received multiple treatment courses; of these, 1890, 1043, 425, and 133 patients received at least two, three, four, or five courses without an increase in total adverse events, serious adverse events, or overall infection rates [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/34\">",
"       34",
"      </a>",
"      ]. Clinically significant hypogammaglobulinemia occurred in a very small number of patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hypogammaglobulinemia and infection'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011464\">",
"    <span class=\"h4\">",
"     Retreatment of initial nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients need at least two courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to achieve a formal response to treatment. We feel it is important to distinguish between patients who do not show any response to rituximab (as assessed by inflammatory symptoms, joint counts, and serum CRP levels) and patients who show some response but do not fulfill DAS28 response criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/30\">",
"     30",
"    </a>",
"    ]. A second cycle of rituximab treatment can be considered in the latter group of patients at six months, particularly if they are seropositive and if other treatment options are not available or are felt to be less adequate in the individual patient. Whether this group of patients would benefit from a second course of treatment earlier than six months is not known. The range of evidence includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small observational study of 30 patients found that a lack of a response to an initial course of treatment predicted that retreatment would also be ineffective. Patients with recurrent or persistent active disease, as defined by the European League Against Rheumatism (EULAR) response criteria, were treated with up to three courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      at intervals of at least six months, regardless of whether they responded to the first course of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/35\">",
"       35",
"      </a>",
"      ]. Of the 24 patients who qualified for retreatment, seven did not respond to the initial course of treatment, and these patients remained generally nonresponsive to subsequent treatment courses. In contrast, the 17 initial responders experienced responses to further treatment similar to those which followed the first course.",
"      <br/>",
"      <br/>",
"      However, in subsequent studies, retreatment of patients who did not respond by EULAR criteria to a first cycle of rituximab was associated with a response by the same criteria in several of the patients to a second course of treatment administered usually after week 24.",
"     </li>",
"     <li>",
"      In a small study, retreatment of 25 of 38 nonresponders to a first cycle of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy led to a response by EULAR criteria in 72 percent (18 of 25) six months after a second cycle of rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/36\">",
"       36",
"      </a>",
"      ]. Second cycles of rituximab were administered at least six months after the first cycle, at a time when B cell counts were lower than baseline. All patients were positive for RF, anti-CCP antibodies, or both. When first-cycle nonresponders were compared with first-cycle responders, nonresponders had higher circulating levels of plasmablasts at baseline and were less likely to have reached complete depletion, as assessed by high-sensitivity flow cytometry (CD19 count less than 0.0001 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      ie, below 0.1",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      following the first rituximab infusion (12 versus 88 percent). Retreatment of nonresponders was associated with a higher number of patients achieving complete depletion (38 versus 12 percent).",
"     </li>",
"     <li>",
"      In the pooled retrospective analysis of data from randomized trials and their extension phases referred to above, up to 60 percent of patients that had not responded by EULAR criteria six months after a first course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      achieved a response six months after receiving a second course [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effects on B cells and antibodies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Importance of B cell depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within two to four weeks after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    infusion, B cell numbers in peripheral blood, when measured by standard techniques, fall to unmeasurable levels in most patients and remain low for 6 to 12 months (or longer in some patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When more sensitive techniques are used, incomplete B cell depletion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    appears to be more common than initially appreciated and is associated with reduced efficacy. This was illustrated in a study of 60 RA patients treated with rituximab (two infusions of 1 g each given two weeks apart) in which the degree of B cell depletion was assessed by use of a high sensitivity minimal residual disease (MRD) flow cytometry technique used to evaluate patients with leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/37\">",
"     37",
"    </a>",
"    ]. Complete B cell depletion was defined as levels below 0.1",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    using the MRD protocol and 5",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    by conventional cytometry.",
"   </p>",
"   <p>",
"    More patients with residual B cells were identified after the first and second infusion by the MRD technique than conventional techniques (63 versus 6 percent and 18 versus 6 percent, respectively). After the first infusion, moderate to good clinical responses (by European League Against Rheumatism [EULAR] criteria) were identified more often in patients with complete compared with partial B cell depletion with the MRD technique (87 versus 59 percent at 3 months and 59 versus 21 percent at 12 months). Patients who only attained complete B cell depletion after the second infusion had outcomes similar to those in patients who never achieved complete B cell depletion.",
"   </p>",
"   <p>",
"    Relapse of active RA may coincide with recovery of B cells in peripheral blood or occur at a variable time after. It is usually associated with rising autoantibody levels. This was illustrated in a report of 22 patients treated with a variety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -based regimens. Clinical relapses were preceded by resolution of B cell lymphopenia and rising serum levels of RF (IgM and IgA subtypes) and anti-citrullinated peptide antibodies (anti-CCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B cell depletion in synovial tissue has been evaluated in RA patients. The ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to deplete synovial B cells appears in small series to be more variable than the effect on peripheral blood B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The clinical significance of this effect is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     RF and serum immunoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factor (RF) levels are reduced by a greater proportion than are serum immunoglobulin (Ig) levels by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    treatment. Although mean Ig levels decrease in patients who have received a single course of therapy, only a small proportion of such patients have levels that are below the lower limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/7,8,16\">",
"     7,8,16",
"    </a>",
"    ]. As an example, in the REFLEX trial, the mean RF level fell by 40 to 50 percent and remained depressed for up to 24 weeks in patients receiving both rituximab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) compared with those receiving placebo and MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/16\">",
"     16",
"    </a>",
"    ]. Subnormal IgM levels were noted in 5.5 percent of patients treated with rituximab plus MTX versus 1.9 percent of patients treated with MTX and placebo, while none of the controls and less than 1 percent of patients treated with rituximab had depressed IgA or IgG levels. Repeated courses of rituximab may lead to further, usually modest, reduction in serum IgG and IgA levels, but IgM may be reduced to a greater degree [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/34\">",
"     34",
"    </a>",
"    ]. These effects are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hypogammaglobulinemia and infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most predictable side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a constellation of",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    that occurs within the initial 30 to 120 minutes of the first exposure. Infusion reactions are particularly likely during the first infusion, occurring in up to 30 to 45 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/8\">",
"     8",
"    </a>",
"    ]. The most common symptoms are headache, fever, chills, sweats, skin rash, dyspnea, mild hypotension, nausea, rhinitis, skin rash, pruritus, asthenia, back pain, and a mild sensation of tongue and throat swelling (angioedema). Bronchospasm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hypotension are present in less than 10 percent of cases, and less than 5 percent of reactions are severe (grade 3 or 4) or suggestive of anaphylaxis.",
"   </p>",
"   <p>",
"    Certain signs and symptoms are highly suggestive of anaphylaxis, and their presence should be specifically sought when evaluating a patient with an infusion reaction: urticaria, repetitive cough, wheeze, and throat",
"    <span class=\"nowrap\">",
"     tightness/change",
"    </span>",
"    in voice. These stereotypical signs and symptoms result from the release of mediators from mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils. In contrast, fever and muscular pain are not features of anaphylaxis, and the presence of these suggests the reaction is a standard infusion reaction, or SIR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H6#H6\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Signs and symptoms of anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of these SIRs are thought to be related to an antibody-antigen interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (the antibody) and CD20 (the antigen) on lymphocytes, resulting in cytokine release from B cells. In most patients, the reaction complex is mild, is brief, lacks symptoms to suggest anaphylaxis, and resolves completely when drug infusion is withheld.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to identify patients who are likely to develop infusion reactions have not been successful. The first step in prevention is a gradual increase in dosing during the infusion period. The first infusion is begun at a rate of 50",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"    If no evidence of hypersensitivity or other reaction is evident, the rate may be increased by 50",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    every 30 minutes to a maximum of 400",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"    If the initial infusion is well-tolerated, subsequent infusions can be started at a rate of 100",
"    <span class=\"nowrap\">",
"     mg/hour,",
"    </span>",
"    and the rate can be increased by 100",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    every 30 minutes to a maximum of 400",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    if there is no evidence of hypersensitivity.",
"   </p>",
"   <p>",
"    Premedication with antihistamines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , with or without a glucocorticoid, can help prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the severity of infusion reactions, particularly SIRs. In contrast, anaphylaxis is generally not prevented by premedication, although the severity of the reaction may be reduced in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H21#H21\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Prophylaxis of infusion reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These premedication regimens have been empirically derived rather than established through randomized trials. Furthermore, they are not completely protective, even for SIRs. Therefore, despite the use of premedication, patients must be monitored closely during and immediately following all infusions. In our experience, close monitoring of the patient during the infusion, as recommended by the manufacturer, and adjustment of the dose, if symptoms or signs suggesting an infusion reaction occur, allow completion of the treatment in the great majority of patients.",
"   </p>",
"   <p>",
"    Premedication protocols have largely been derived from the experience in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for malignancy. A standard premedication regimen in patients with RA is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (650 mg orally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (100 mg) given 30 minutes before at least the first and second doses of rituximab. Standard premedications can be eliminated during subsequent infusions if reactions are not evident with the initial doses. Although, at some institutions, routine premedication also includes an H2-receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    50 mg IV), we have not found this necessary in our experience. In patients with a previous history of infusion reactions, we give the infusion slowly with close monitoring of symptoms.",
"   </p>",
"   <p>",
"    The efficacy of pretreatment with H1- and H2-antihistamines has not been assessed in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for RA. The benefit of glucocorticoids was addressed in the placebo-controlled DANCER trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/15\">",
"     15",
"    </a>",
"    ]. A single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (100 mg) given 30 minutes before beginning the rituximab infusion reduced the frequency and intensity of first infusion-associated events; oral glucocorticoids (ie, 60 mg daily for one week following the first infusion and 30 mg daily for a week after the second infusion of rituximab) conferred no additional benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mild reactions occurring during a treatment can be managed by temporarily stopping the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    infusion, waiting for symptoms to completely subside, and restarting the infusion at one-half of the initial rate. An additional dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (625 mg orally) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally) is typically given at the time of the reaction. If symptoms do not recur, the infusion may be increased by 50",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    to the maximal rate of 400",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Additional",
"    treatment, including saline infusion, inhaled bronchodilators, intramuscular epinephrine, and parenteral glucocorticoids may be required in the event of a more serious reaction with bronchospasm, hypotension, or other signs and symptoms suggestive of anaphylaxis. The emergent management of anaphylaxis in adults is detailed in the table (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 1",
"    </a>",
"    ). Although severe anaphylactic reactions and severe bronchospasm are rare, these supplies should be available at the patient's bedside during the entire",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    infusion to respond to infusion reactions. Recognition and management of anaphylaxis are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Holding antihypertensives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the frequency of mild to moderate hypotension occurring in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    infusions, patients should be instructed not to take their antihypertensive medications the morning of the rituximab infusion. In addition, the infusion should be administered with the patient reclining or supine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypogammaglobulinemia and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total immunoglobulin (Ig) levels following one course of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    usually remain within the normal range, but repeated courses of therapy are associated with an increasing risk of hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/3,16,31,34\">",
"     3,16,31,34",
"    </a>",
"    ]. Similarly, a 2009 meta-analysis of three trials including 1143 patients with RA found no increase in serious infections associated with use of rituximab with or without MTX compared with MTX plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/40\">",
"     40",
"    </a>",
"    ], but other studies have found that repeated courses of rituximab may be associated with a higher rate of serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These points were best illustrated in a pooled analysis of 2578 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    together with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in clinical trials for RA, some of whom received rituximab for up to five cycles over six years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of IgM, IgG, and IgA below the lower limits of normal occurred at any point during follow-up in 23, 5, and less than 1 percent of patients, respectively.",
"     </li>",
"     <li>",
"      The proportion of patients with low IgM six months after each course of treatment increased successively from 10 percent after the first course to 40 percent after the fifth. Low IgM levels were NOT associated with serious infection.",
"     </li>",
"     <li>",
"      The proportion of patients with low IgG six months after each course of treatment remained stable, varying from 3 to 6 percent. Sustained low IgG levels were present for at least one year in 32 patients (1 percent), of whom 5 developed very low IgG levels (less than 3",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"     <li>",
"      Serious infections occurred in 6 of 32 patients with sustained low IgG; however, given the low number of these patients, this was not statistically significant. Older age was an independent predictor of both serious infection and sustained low IgG levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior subgroup analyses of smaller numbers of patients had not revealed an increased risk of infections with low IgM or IgG, although individual patients with hypogammaglobulinemia associated with repeated courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy and repeated infectious episodes had been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/3,16,31\">",
"     3,16,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We thus exercise particular caution when considering a repeat course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the presence of low IgG, particularly if less than 5",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    or in the presence of other risk factors for repeated or serious infections, such as older age and glucocorticoid use. Immunoglobulin levels should be measured before treatment and whenever retreatment is being considered. They should also be measured if the patient develops any serious or recurrent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241650363\">",
"    <span class=\"h3\">",
"     Opportunistic infections and viral reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;No increase in the incidence of opportunistic infections was apparent in clinical trials for RA. However, among patients with RA and other rheumatic diseases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been associated in case reports with severe Pneumocystis carinii (P. jirovecii) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/41\">",
"     41",
"    </a>",
"    ], cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/42\">",
"     42",
"    </a>",
"    ], cytomegalovirus colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/43\">",
"     43",
"    </a>",
"    ], and progressive multifocal leukoencephalopathy (PML) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least six patients have been reported with PML in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    treatment for RA, for an estimated incidence of less than 1 in 20,000 to less than 1 in 25,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Most patients had received other immunosuppressive drugs, sometimes concurrently; two had a history of malignancy and prior chemotherapy, radiotherapy or both; and several were lymphopenic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/47\">",
"     47",
"    </a>",
"    ]. However, one had early RA, naive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or other disease-modifying antirheumatic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/47\">",
"     47",
"    </a>",
"    ]. We would consider the diagnosis of PML in any patient treated with rituximab who develops new neurologic manifestations, although these events are rare and PML is more strongly associated with deficient cellular immunity. The evaluation and management of such patients is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link&amp;anchor=H2#H2\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     \"Rituximab: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactivation of hepatitis B infection is extremely rare but has been reported in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Reports are more common among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -treated patients with lymphoma or other malignancies and also include some patients with initially only serologic evidence of resolved past hepatitis B infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vaccination responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses to inactivated viral or bacterial vaccines may be impaired following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In patients in whom vaccination is indicated (eg, for hepatitis B, influenza, or pneumococcal pneumonia), we suggest immunizing patients at least four weeks before the administration of rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/25\">",
"     25",
"    </a>",
"    ]. If vaccination is indicated in a patient who has already received rituximab, responses may be blunted until B cell recovery occurs (ie, 6 to 12 months). Thus, vaccines could be given and responses then assessed, or vaccination could be postponed until B cells have recovered. The effects of rituximab upon vaccine responses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    were evaluated in a randomized trial involving 103 patients with rheumatoid arthritis in whom recall responses to tetanus toxoid in patients treated with rituximab plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (tested after 36 weeks) were comparable to those in patients treated with methotrexate alone (tested after 12 weeks), and comparably preserved delayed-type hypersensitivity responses to Candida albicans were present on skin testing in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/52\">",
"     52",
"    </a>",
"    ]. However, the proportion of patients with responses to pneumococcal polysaccharide and neoantigen were reduced in the patients who had also received rituximab (57 versus 82, and 47 versus 93 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Human antichimeric antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of human antichimeric antibodies (HACA) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with RA and SLE treated with this agent is higher than that previously noted in patients treated for lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/53\">",
"     53",
"    </a>",
"    ]. As an example, in the dose ranging study previously cited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/15\">",
"     15",
"    </a>",
"    ], HACA were detectable in 0.7 percent, 4.2 percent, and 2.7 percent of those receiving placebo, low-dose rituximab, and high-dose rituximab, respectively, compared with 0.6 percent in a group of patients treated for relapsed lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/54\">",
"     54",
"    </a>",
"    ]. In the REFLEX trial, 4.3 percent of patients treated with MTX, glucocorticoids, and rituximab had detectable HACA at the end of 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greater incidence of HACA formation in patients with RA may relate to the higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    used in lymphoma treatment regimens. For B cell lymphomas, the approved dosing regimen is 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly times four doses. In addition, patients with lymphoma typically receive more potent immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical significance of HACA development in patients with RA is not clear. However, experience with other chimeric agents, and with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in other diseases, suggests the following possible consequences of HACA formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase in the risk of infusion reactions. This has been observed with a different chimeric monoclonal antibody,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decrease in the therapeutic efficacy caused by enhanced clearance of the therapeutic agent. This phenomenon has been noted by some observers in patients with systemic lupus erythematosus and has been reported in the literature in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H334601#H334601\">",
"       \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Rituximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less common adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include serious mucocutaneous reactions (Stevens-Johnson syndrome, vesiculobullous dermatitis, and toxic epidermal necrolysis). These rare adverse effects usually present 1 to 13 weeks after therapy. Serum sickness (delayed type III hypersensitivity) reactions have been reported following rituximab therapy in rare cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Additionally, cases of organizing pneumonia in patients treated with rituximab have been described, one of whom was treated for RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late-onset of neutropenia can occur in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -treated patients with RA and other rheumatic disorders and is associated with a high incidence of infections; it is well-recognized as a complication of rituximab therapy in patients treated for lymphoid malignancy. In a cohort of patients treated with rituximab in Sweden for various rheumatic diseases, late-onset neutropenia (40 to 362 days following rituximab administration, with a median of 102 days) was found in 3 percent of patients with RA in association with marked B cell depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/60\">",
"     60",
"    </a>",
"    ]. We have also seen a small number of cases of early (within one month), in addition to late-onset, neutropenia. Although most were mild, a few were severe and required admission for treatment with granulocyte-colony stimulating factor and antibiotics. Drug-induced neutropenia and other adverse effects of rituximab are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link&amp;anchor=H7617817#H7617817\">",
"     \"Drug-induced neutropenia and agranulocytosis\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     \"Rituximab: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER B CELL DEPLETING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical development of human anti-CD20 monoclonal antibodies is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ofatumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    is undergoing clinical trials to assess dosing, efficacy, and safety when used in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. Results of a combined phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study investigating the safety and efficacy of three doses of ofatumumab indicated that it was clinically effective in patients with active RA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/64\">",
"     64",
"    </a>",
"    ]. The most common adverse effects were mild to moderate infusion reactions, which were very common. Risk of infections was not increased compared with placebo. Additional trials are required before its use should be considered in RA, although this drug is approved in the United States for the treatment of refractory chronic lymphocytic leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ocrelizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocrelizumab is a recombinant human anti-CD20 monoclonal antibody that binds to a different, but overlapping, CD20 epitope than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/63\">",
"     63",
"    </a>",
"    ]. It was designed to optimize B cell depletion by modification of the Fc region, which enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity compared with rituximab. The manufacturers have discontinued development of ocrelizumab for use in rheumatoid arthritis because of safety concerns raised by the occurrence of serious and opportunistic infections, including fatal infections, in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INHIBITORS OF B CELL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic response seen with B cell depletion using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    suggests that other approaches that interfere with B cell function or interfere with B cell trafficking to the joints or other sites of inflammation in patients with RA may prove useful. B cell targets other than CD20 that have been suggested include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Molecules involved in intracellular signaling pathways",
"     </li>",
"     <li>",
"      Toll-like receptors",
"     </li>",
"     <li>",
"      Costimulatory receptor or ligands (eg, CD80, CD86)",
"     </li>",
"     <li>",
"      Surface markers other than CD20 (eg, CD79, CD22)",
"     </li>",
"     <li>",
"      B cell survival promoting molecule (B lymphocyte stimulator, BLyS, also known as BAFF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Belimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=see_link\">",
"     Belimumab",
"    </a>",
"    is an anti-BLyS monoclonal antibody (Benlysta, formerly LymphoStat-B) approved for use in patients with systemic lupus erythematosus that has also been used in a dose ranging, phase II trial in RA published in an abstract form in 2005",
"    <span class=\"nowrap\">",
"     (ACR/ARHP",
"    </span>",
"    Annual Scientific Meeting). However, the efficacy observed at 24 weeks was rather modest. Although its possible role in the treatment of RA is not known, it may prove to be useful in the future in combination regimens with other B cell targeting agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H48780341#H48780341\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Belimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Atacicept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atacicept is a recombinant fusion protein comprised of a portion of the transmembrane activator and calcium-modulator and an immunoglobulin chain (TACI-Ig or atacicept). Atacicept targets molecules on the B cell surface that promote B cell survival (BLyS and APRIL). Pharmacokinetic data from a phase I trial suggested that repeated dosing of TACI-Ig produces significant reductions in immunoglobulin levels, including a 41 to 44 percent decrease in rheumatoid factor in the highest dose group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/71\">",
"     71",
"    </a>",
"    ]. However, two randomized phase II studies of patients with active RA who had inadequate responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and to tumor necrosis factor inhibition, respectively, failed to achieve their primary clinical efficacy endpoints, despite evidence of biologic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/40/21130/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B cell depletion using the anti-CD20 chimeric monoclonal antibody,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , is efficacious for patients with RA and is most useful in patients with persistently active disease despite adequate trials with other disease-modifying antirheumatic drugs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical efficacy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"       \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have rheumatoid factor or antibodies to citrullinated peptides detectable in serum (seropositive patients) are more likely to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      than seronegative patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with RA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      infusions are typically given to those who are already receiving weekly MTX. Two doses of rituximab (1000 mg) given intravenously, two weeks apart, are recommended by the manufacturer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There remains uncertainty as to when to repeat a cycle of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      treatment. Retreatment is usually considered in patients who respond to an initial cycle of rituximab treatment. Patients retreated based upon a treatment-to-target approach show better responses over time compared with patients only retreated when there has been clear worsening of signs and symptoms of active disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Retreatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      are common, particularly with the first infusion, and may represent a response to cytokines released during B cell depletion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premedication may reduce the incidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the severity of infusion reactions. We use a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (1000 mg once) orally and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"       chlorpheniramine",
"      </a>",
"      (10 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (100 mg) intravenously 30 minutes prior to each infusion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of infusion reactions in patients with RA is analogous to that in patients with malignant B cell disorders. Saline solution for infusion, bronchodilators for inhalation, epinephrine for intramuscular injection, and glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      100 mg) for intravenous administration may be required in the event of a serious hypersensitivity reaction with bronchospasm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension. These agents should be available at the bedside throughout the infusion.",
"     </li>",
"     <li>",
"      Most reactions occurring during a treatment can be managed by temporarily stopping the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      infusion, waiting for symptoms to completely subside, and restarting the infusion at one-half of the initial rate.",
"     </li>",
"     <li>",
"      Other treatments for RA that target B cells are being investigated. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Other B cell depleting agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/1\">",
"      Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/2\">",
"      Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002; 46:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/3\">",
"      Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/4\">",
"      Beech JT, Andreakos E, Ciesielski CJ, et al. T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFkappaB: implications for rheumatoid arthritis. Arthritis Res Ther 2006; 8:R168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/5\">",
"      Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/6\">",
"      Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/7\">",
"      Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/8\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/9\">",
"      Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/10\">",
"      Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/11\">",
"      Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/12\">",
"      Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/13\">",
"      Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/14\">",
"      De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/15\">",
"      Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/16\">",
"      Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/17\">",
"      Mariette X, Kivitz A, Isaacs J, et al. Effectiveness of rituximab + methotrexate in patients with early active rheumatoid arthritis and disease characteristics associated with poor outcomes. Arthritis Rheum 2009; 60:S631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/18\">",
"      Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/19\">",
"      Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012; 79:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/20\">",
"      Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/21\">",
"      Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67 Suppl 3:iii2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/22\">",
"      Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/23\">",
"      Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010; 69:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/24\">",
"      Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008; 59:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/25\">",
"      Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/26\">",
"      Vital EM, Dass S, Rawstron AC, et al. Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis. Ann Rheum Dis 2008; 67(Suppl II):90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/27\">",
"      Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/28\">",
"      Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69:387.",
"     </a>",
"    </li>",
"    <li>",
"     Chatzidionysiou K, Carli CC, Van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs in an observational cohort: The SARASTRA study (Abstract). Presented at the 2009 EULAR scientific meeting, Stockholm Sweden.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/30\">",
"      Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011; 25:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/31\">",
"      Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/32\">",
"      Pua YH, Wrigley TV, Collins M, et al. Self-report and physical performance measures of physical function in hip osteoarthritis: relationship to isometric quadriceps torque development. Arthritis Rheum 2009; 61:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/33\">",
"      Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 2011; 50:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/34\">",
"      van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/35\">",
"      Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008; 58:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/36\">",
"      Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/37\">",
"      Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/38\">",
"      Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/39\">",
"      Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/40\">",
"      Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/41\">",
"      Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/42\">",
"      Wingfield T, Jani M, Krutikov M, et al. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford) 2011; 50:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/43\">",
"      Vallet H, Houitte R, Azria A, Mariette X. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rheumatol 2011; 38:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/44\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/45\">",
"      Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60:3225.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/default.htm (Accessed on October 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/47\">",
"      Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/48\">",
"      Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/49\">",
"      Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/50\">",
"      Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/51\">",
"      Gelinck LB, Teng YK, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/52\">",
"      Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/53\">",
"      Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/54\">",
"      McLaughlin P, Grillo-L&oacute;pez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/55\">",
"      Driver CB, Weisman MH. Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment? Nat Clin Pract Rheumatol 2006; 2:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/56\">",
"      Tahir H, Rohrer J, Bhatia A, et al. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005; 44:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/57\">",
"      D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/58\">",
"      Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/59\">",
"      Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine 2008; 75:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/60\">",
"      Tesfa D, Ajeganova S, H&auml;gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/61\">",
"      Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/62\">",
"      Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/63\">",
"      Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/64\">",
"      &Oslash;stergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010; 62:2227.",
"     </a>",
"    </li>",
"    <li>",
"     Roche media release. Basel, 19 May 2010. www.roche.com/media/media_releases/med-cor-2010-05-19.htm (Accessed on June 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/66\">",
"      Carter RH. B cell signalling as therapeutic target. Ann Rheum Dis 2004; 63 Suppl 2:ii65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/67\">",
"      Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002; 1:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/68\">",
"      Cyster JG. Homing of antibody secreting cells. Immunol Rev 2003; 194:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/69\">",
"      Borland G, Cushley W. Positioning the immune system: unexpected roles for alpha6-integrins. Immunology 2004; 111:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/70\">",
"      Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115:3083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/71\">",
"      Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/72\">",
"      van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/40/21130/abstract/73\">",
"      Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011; 63:1793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7501 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21130=[""].join("\n");
var outline_f20_40_21130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RITUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Combination with leflunomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rituximab versus a second TNF inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Retreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7011412\">",
"      Retreatment of responders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7011464\">",
"      Retreatment of initial nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effects on B cells and antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Importance of B cell depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - RF and serum immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Holding antihypertensives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypogammaglobulinemia and infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H241650363\">",
"      - Opportunistic infections and viral reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vaccination responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Human antichimeric antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER B CELL DEPLETING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ofatumumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ocrelizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INHIBITORS OF B CELL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Belimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Atacicept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 1\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=related_link\">",
"      Rituximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_40_21131="Differential dx adnexal mass";
var content_f20_40_21131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of adnexal masses in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extraovarian mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrosalpinx or tuboovarian abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraovarian cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal inclusion cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pedunculated fibroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diverticular abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendiceal abscess or tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fallopian tube cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory or malignant bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic kidney",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ovarian mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple or hemorrhagic physiologic cysts (eg, follicular, corpus luteum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometrioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theca lutein cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign, malignant, or borderline neoplasms (eg, epithelial, germ cell, sex-cord)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastatic carcinoma (eg, breast, colon, endometrium)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21131=[""].join("\n");
var outline_f20_40_21131=null;
var title_f20_40_21132="Predict noncompliance CPAP";
var content_f20_40_21132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General predictors of noncompliance with nasal CPAP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Patient related factors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Failure to understand the importance of the therapy.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Failure to understand instructions concerning the therapy.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Concomitant self-administration of prescription or non-prescription medications or alcohol.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Social Isolation, thus lack of social support. (Patients with supportive families have been shown to be more compliant with prescription drugs - data not available for CPAP use).",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Feeling ill, or being too tired to use the therapy.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Physical limitations, including vision, hearing, hand coordination.",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Therapy and medication related factors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Complexity of therapy, in device use, or medication dosing.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased rate of adverse reactions. (Device use has complications, and the provider needs to meet with the patient periodically to determine adverse events and help address these issues).",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Characteristics of illness; long-term or chronic illnesses are a problem, as compliance decreases over time.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Expensive therapy (Only a problem when a patient must pay out of pocket or has not met the deductible.)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lack of efficacy.",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Health professional related factors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Poor relationship with patient.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Expression of doubt concerning therapeutic potential.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Unwillingness to educate patients.",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lack of knowledge of medications the patient is taking or has access to. (Sedatives and alcohol can compound OSA, and their use should be evaluated).",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21132=[""].join("\n");
var outline_f20_40_21132=null;
var title_f20_40_21133="NNS to prevent cancer death";
var content_f20_40_21133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Number need to screen to prevent cancer-specific death",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 75",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 80",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 85",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Mammography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper quartile life expectancy",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        417",
"       </td>",
"       <td>",
"        1066",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle quartile life expectancy",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        242",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        533",
"       </td>",
"       <td>",
"        2131",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower quartile life expectancy",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        642",
"       </td>",
"       <td>",
"        1361",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Papanicolaou",
"smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper quartile life expectancy",
"       </td>",
"       <td>",
"        533",
"       </td>",
"       <td>",
"        934",
"       </td>",
"       <td>",
"        1177",
"       </td>",
"       <td>",
"        1694",
"       </td>",
"       <td>",
"        2946",
"       </td>",
"       <td>",
"        7528",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle quartile life expectancy",
"       </td>",
"       <td>",
"        728",
"       </td>",
"       <td>",
"        1521",
"       </td>",
"       <td>",
"        2113",
"       </td>",
"       <td>",
"        3764",
"       </td>",
"       <td>",
"        15,056",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower quartile life expectancy",
"       </td>",
"       <td>",
"        1140",
"       </td>",
"       <td>",
"        4070",
"       </td>",
"       <td>",
"        8342",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Fecal",
"occult blood test (women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper quartile life expectancy",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        262",
"       </td>",
"       <td>",
"        455",
"       </td>",
"       <td>",
"        1163",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle quartile life expectancy",
"       </td>",
"       <td>",
"        263",
"       </td>",
"       <td>",
"        340",
"       </td>",
"       <td>",
"        408",
"       </td>",
"       <td>",
"        581",
"       </td>",
"       <td>",
"        2326",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower quartile life expectancy",
"       </td>",
"       <td>",
"        577",
"       </td>",
"       <td>",
"        1046",
"       </td>",
"       <td>",
"        1805",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Fecal",
"occult blood test (men)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper quartile life expectancy",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        207",
"       </td>",
"       <td>",
"        277",
"       </td>",
"       <td>",
"        554",
"       </td>",
"       <td>",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle quartile life expectancy",
"       </td>",
"       <td>",
"        255",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        525",
"       </td>",
"       <td>",
"        945",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower quartile life expectancy",
"       </td>",
"       <td>",
"        630",
"       </td>",
"       <td>",
"        1877",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Number needed to screen refers to the number needed to screen over the remaining lifetime to prevent one cancer-specific death for women and men at selected ages and life expectancy quartiles. The life expectancy quartiles are those shown in the accompanying figure. Details about how the numbers are derived are provided in the text of the study.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Walter, LC, Covinsky, KE, JAMA 2001; 285:2750.&nbsp;",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21133=[""].join("\n");
var outline_f20_40_21133=null;
var title_f20_40_21134="Pelvic pain in the pregnant adolescent female with vaginal bleed";
var content_f20_40_21134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Pelvic pain in the pregnant adolescent female with vaginal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21134=[""].join("\n");
var outline_f20_40_21134=null;
var title_f20_40_21135="Paraphimosis PI";
var content_f20_40_21135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Paraphimosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The foreskin can sometimes get stuck below the head of the penis. This is called &ldquo;paraphimosis.&rdquo; If this happens to you or your son, do not try to force the skin to move. Go to a hospital emergency room for treatment. If this problem is not treated right away, it can cause permanent damage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_40_21135=[""].join("\n");
var outline_f20_40_21135=null;
